{"title": "PDF", "author": "PDF", "url": "https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mundhoehlenkarzinom/S3-Mundhoehlenkarzinom-OL-Kurzversion_.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  1 \n0 \nKurzversion   \n \n \n \n \nMundh\u00f6hlen karzinom  \n\u201eDiagnostik und Therapie des \nMundh\u00f6hlenkarzinoms \u201c \nAWMF -Register -Nummer   007-100OL \nVersion 2.0 11.2012  \n \n   \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  2 \nInhaltsverzeichnis  \n1. Informationen zu dieser Kurzversion  ................................ ....................  4 \n1.1. Herausgeber  ................................ ................................ ................................ .........................  4 \n1.2. Federf\u00fchrende Fachgesellschaft  ................................ ................................ .............................  4 \n1.3. Finanzierung der Leitlinie  ................................ ................................ ................................ ...... 4 \n1.4. Kontakt   ................................ ................................ ................................ ............................  4 \n1.5. Besonderer Hinweis  ................................ ................................ ................................ ...............  5 \n1.6. weitere Leitliniendokumente  ................................ ................................ ................................ .. 5 \n1.7. Verantwortlichkeiten  ................................ ................................ ................................ .............  6 \n1.7.1.  Autoren dieser Leitlinie  ................................ ................................ ................................ ... 6 \n1.7.2.  Methodische Begleitung  ................................ ................................ ................................ .. 6 \n1.8. Eingebundene Fachgesellschaften und Organisationen  ................................ ...........................  6 \n1.9. Schema der Evidenzgraduierung nach  SIGN ................................ ................................ ...........  8 \n1.10.  Graduierung der Empfehlungen  ................................ ................................ .............................  8 \n2. Konsentierte und abgestimmte Empfehlungen und Statements  ..............  9 \n2.1. Risikofaktoren  ................................ ................................ ................................ .......................  9 \n2.2. Screening und Pr\u00e4vention  ................................ ................................ ................................ ...... 9 \n2.3. Prim\u00e4rdiagnostik  ................................ ................................ ................................ .................  10 \n2.4. Bildgebende Verfahren und weitere Diagnostik  ................................ ................................ .... 10 \n2.5. Bildgebende Verfahren und Diagnostik zum Ausschluss synchroner Zwei ttumoren, \nFernmetastasen, unbekannter Prim\u00e4rtumoren (CUP) und Rezidive  ................................ ......................  11 \n2.6. Biopsie und Histopathologie  ................................ ................................ ................................  12 \n2.7. Behandlungsempfehlungen  ................................ ................................ ................................ . 13 \n2.8. Chirurgische Behandlung des Pri m\u00e4rtumors  ................................ ................................ .........  13 \n2.9. Halslymphknotenausr\u00e4umung  ................................ ................................ .............................  14 \n2.10.  Rekonstruktion ................................ ................................ ................................ ....................  16 \n2.11.  Strahlentherapie  ................................ ................................ ................................ ..................  17 \n2.12.  Strahlentherapie in Kombination mit Chemotherapie  ................................ ...........................  17  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  3 \n2.13.  Pr\u00e4vention und Behandlung strahlenbedingter Begleiterscheinungen  ................................ .... 18 \n2.14.  Behandlung des lokoregion\u00e4ren Rezidivs  ................................ ................................ .............  19 \n2.15.  Palliative und palliativmedizinische Behandlung  ................................ ................................ ... 19 \n2.16.  Nachsorge und Rehabilitation  ................................ ................................ ..............................  20 \n2.16.1.  Nachsorge  ................................ ................................ ................................ ....................  20 \n2.16.2.  Kaufunktionelle Rehabilitation  ................................ ................................ ......................  20 \n2.16.3.  Sprech - und Schluckrehabilitation  ................................ ................................ ................  20 \n2.16.4.  Ern\u00e4hrungstherapie  ................................ ................................ ................................ ...... 21 \n2.16.5.  Psychosoziale Beratung und Betreuung  ................................ ................................ .........  21 \n3. Qualit\u00e4tsindikatoren  ................................ ................................ ...........  22 \n4. Referenzen  ................................ ................................ ........................  24 \n Herausgeber  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  4 \n1. Informationen zu dieser Kurzversion  \n1.1. Herausgeber  \n \nLeitlinienprogramm Onkologie  \nder AWMW, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V.  \nOffice: c/o Deutsche Krebsgesellschaft e.V.  \nKuno -Fischer -Stra\u00dfe 8  \n14057 Berlin  \nleitlinienprogramm@krebsgesellschaft.de  \nwww.leitlinienprogramm -onkologie.de  \n \n1.2. Federf\u00fchrende Fachgesellschaft  \nDeutsche Gesellschaft f\u00fcr Mund -, Kiefer - und Gesichtschirurgie  \n \n1.3. Finanzierung der Leitlinie  \nDiese Leitlinie wurde von der Deutschen Krebshilfe im Rahmen des Onkologischen \nLeitlinienprogramms gef\u00f6rdert . \n \n1.4. Kontakt  \nLeitlinienkoordination:  \nUniv. -Prof. Dr. med. Dr. med. dent. Klaus -Dietrich Wolff  \nKlinik und Poliklinik f\u00fcr Mund, -Kiefer - und Gesichtschirurgie  \nKlinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen  \nIsmaninger Str. 22   \n81675 M\u00fcnchen  \nTel.: 004989 4140 -2921  \nFax: 004989 4140 -4993  \nwolff@mkg.med.tum.de  \nwww.med.tum.de   Besonderer Hinweis  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  5 \n1.5. Besonderer Hinweis  \nDie Medizin unterliegt einem fortw\u00e4hrenden Entwicklungsprozess, sodass alle Angaben, \ninsbesondere zu diagnostischen und therapeutischen Verfahren, immer nur dem Wissensstand \nzurzeit der Drucklegung der VersorgungsLeitlinie entsprechen k\u00f6nnen. Hinsichtlich der \nangegebenen Empfehlungen zur Therapie und der Auswahl sowie Dosierung von Medikamenten \nwurde die gr\u00f6\u00dftm\u00f6gliche Sorgfalt beachtet. Gleichwohl werden die Benutzer aufgefordert, die \nBeipackzettel und Fachinformationen der Hersteller zur Kontrolle heranzuz iehen und im Zweifelsfall \neinen Spezialisten zu konsultieren. Fragliche Unstimmigkeiten sollen bitte im allgemeinen Interesse \nder OL -Redaktion mitgeteilt werden.  \nDer Benutzer selbst bleibt verantwortlich f\u00fcr jede diagnostische und therapeutische \nApplikati on, Medikation und Dosierung.  \nIn dieser Leitlinie sind eingetragene Warenzeichen (gesch\u00fctzte Warennamen) nicht besonders \nkenntlich gemacht. Es kann also aus dem Fehlen eines entsprechenden Hinweises nicht geschlossen \nwerden, dass es sich um einen freien W arennamen handelt.  \nDie Leitlinie ist in allen ihren Teilen urheberrechtlich gesch\u00fctzt. Jede Verwertung au\u00dferhalb der \nBestimmung des Urhebergesetzes ist ohne schriftliche Zustimmung der OL -Redaktion unzul\u00e4ssig \nund strafbar. Kein Teil des Werkes darf in irg endeiner Form ohne schriftliche Genehmigung der OL -\nRedaktion reproduziert werden. Dies gilt insbesondere f\u00fcr Vervielf\u00e4ltigungen, \u00dcbersetzungen, \nMikroverfilmungen und die Einspeicherung, Nutzung und Verwertung in elektronischen Systemen, \nIntranets und dem I nternet.  \n1.6. weitere Leitliniendokumente  \nDie Inhalte dieser Kurzversion  beziehen sich auf die Langversion der S3 -Leitlinie \n\u201eDiagnostik und Therapie des Mundh\u00f6hlenkarzinoms \u201c, welche \u00fcber folgende Seiten \nzug\u00e4nglich ist  \nhttp://www.awmf.org/leitlinien/aktuelle -leitlinien.html  \nhttp://www.leitlinienprogramm -onkologie.de/OL/leitlinien.html  \nhttp://www.krebsgesellschaft.de/wub_llevidenzbasiert,120884.html  \nhttp://www.dgmkg.de   \nhttp://www.krebshilfe.de  \n \nNeben der Kurzversion gibt es folgende erg\u00e4nzende Dokumente:  \n\uf02d Leitlinienreport  \n\uf02d Langversion  \n\uf02d Patientenleitlinie  (in Bearbeitung, voraussichtlich ab 2013 verf\u00fcgbar)  \nAlle diese Dokumente werden ebenfalls auf den oben genannten Homepages abrufbar \nsein. Verantwortlichkeiten  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  6 \n1.7. Verantwortlichkeiten  \n1.7.1.  Autoren dieser Leitlinie  \nWolff K. -D., Bootz  F., Beck J., Bikowski  K., B\u00f6hme P., Budach  W., Burkhardt  A.,  Danker \nH., Eberhardt  W., Engers  K., Fietkau  R., Frerich  B., Gauler  T., Germann  G., Gittler -\nHebestreit N., Gr\u00f6tz  K., Horch  R., Ihrler  S., Keilholz  U., Lell M., L\u00fcbbe A., Mantey  W., \nNusser -M\u00fcller -Busch R. , Pistne r H., Paradies  K., Reichert  T., Reinert  S., Schliepha ke H., \nSchmitter M., Singer S.,  Westhofen  M., Wirz S.,  Wittlinger  M. \n1.7.2.  Methodische  Begleitung  \n \n1. durch das Leitlinienprogramm Onkologie  Prof. I . Kopp (AWMF), Marburg und \nDr. M . Follmann MPH MSc (DKG), Berlin  \n \n2. durch externe Auftragnehmer  Dr. A . Nast,  S. Rosumeck, Dr. A. Sammain  und \nProf. B . Rzany (Division of Evidence Based Medicine), Berlin  \n \n3. durch den Leitlinienbeauftragten der  federf\u00fchrenden Fachg esellschaft  Prof. H. \nPistner, Erfurt  \n \n1.8. Eingebundene Fachgesellschaften und \nOrganisationen  \n \nDeutsche Gesellschaft f\u00fcr Mund -, Kiefer - und \nGesichtschirurgie  Wolff, K. -D., Gr\u00f6tz K., Reinert, S.  \nDeutsch -\u00d6sterreichisch -Schweizerischer Arbeitskreis f\u00fcr \nTumore im Kiefer -Gesichtsbereich (D\u00d6SAK)  Frerich, B.  \nArbeitsgemeinschaft f\u00fcr Kieferchirurgie  Reichert, T.  \nDeutsche Gesellschaft f\u00fcr Zahn -, Mund - und \nKieferheilkunde  Schliephake, H.  \nDeutsche Gesellschaft f\u00fcr Hals -Nasen -Ohrenheilkunde  Bootz F., Westhofen M.  \nDeutsc he Gesellschaft f\u00fcr Pathologie  Burkhardt A., Ihrler S.  \nDeutsche Gesellschaft f\u00fcr Radioonkologie  Fietkau R., Budach W., Wittlinger M.  \nDeutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie  Keilholz U., Gauler T., Eberhardt W.  \nDeutsche Gesellschaft f\u00fcr Plastische - und \nWiederherstellungschirurgie  Horch R., Germann G.  \nArbeitsgemeinschaft Kopf -Hals der Deutschen \nR\u00f6ntgengesellschaft  Lell M.  \nKOK Paradies K., Gittler -Hebestreit N.  \nArbeitsgemeinschaft f\u00fcr Supportive Onkologie, \nRehabilitation und Sozialmedizi n ASORS  L\u00fcbbe A.  \nAEK Engers K.  Eingebundene Fachgesellschaften und Organisationen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  7 \nBundeszahn\u00e4rztekammer  Boehme, P.  \nKassenzahn\u00e4rztliche Bundesvereinigung  Beck, J.  \nArbeitsgemeinschaft Mund - und Gesichtsschmerz der \nDeutschen Gesellschaft zum Studium des Schmerzes  Schmitter M.  \nDeutsche Schmerzgesellschaft,  \nArbeitskreis Tumorschmerz  Wirz S.  \nPatientenvertretung  Mantey W.  \nDVSG, Nat. Zentrum f\u00fcr Tumorerkrankungen  Bikowski K.  \nDeutscher Bundesverband f\u00fcr Logop\u00e4die  Nusser -M\u00fcller -Busch R.  \nArbeitsgemeinschaft Psychoonkologie in der DKG  (PSO)  Singer S., Danker H.  \n  Schema der Evidenzgraduierung nach SIGN  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  8 \n1.9. Schema der Evidenzgraduierung nach SIGN  \nGrad  Beschreibung  \n1++ Qualitativ hochwertige Metaanalysen, Systematische \u00dcbersichten von RCTs, oder RCTs mit sehr \ngeringem Risiko systematischer Fehler (Bias)  \n1+ Gut durchgef\u00fchrte Metaanalysen, Systematische \u00dcbersichten von RCTs, oder RCTs mit \ngeringem Risiko systematischer Fehler (Bias)  \n1- Metaanalysen, Systematische \u00dcbersichten von RCTs, oder RCTs mit hohem Risiko \nsystematischer Fehler (Bias)  \n1- - Alle-oder-Keiner  \n2++ Qualitati v hochwertige systematische \u00dcbersichten von Fall -Kontroll - oder Kohortenstudien oder  \nQualitativ hochwertige Fall -Kontroll - oder Kohortenstudien mit sehr niedrigem Risiko \nsystematischer Verzerrungen (Confounding, Bias, \u201eChance\u201c) und hoher Wahrscheinlichkeit , dass \ndie Beziehung urs\u00e4chlich ist  \n2+ Gut durchgef\u00fchrte Fall -Kontroll Studien oder Kohortenstudien mit niedrigem Risiko \nsystematischer Verzerrungen (Confounding, Bias, \u201eChance\u201c) und moderater Wahrscheinlichkeit, \ndass die Beziehung urs\u00e4chlich ist  \n2- Fall-Kontroll Studien oder Kohortenstudien mit einem hohen Risiko systematischer \nVerzerrungen (Confounding, Bias, \u201eChance\u201c) und signifikantem Risiko, dass die Beziehung nicht \nurs\u00e4chlich ist  \n3 Nicht -analytische Studien, z.B. Fallberichte, Fallserien  \n4 Expertenmeinung  \n \n1.10.  Graduierung der Empfehlungen  \nEmpfehlungsgrad  Beschreibung  Syntax  \nA Starke Empfehlung  soll \nB Empfehlung  sollte  \n0 Empfehlung offen  kann  \nStatements/Empfehlungen, die auf der Grundlage von Expertenkonsens (nicht auf der \nBasis einer systematischen Suche oder einer Leitlinienadaptation) von der \nLeitliniengruppe beschlossen wurde, sind als solche ausgewiesen mit der Graduierung \n\u201eGCP\u201c. F\u00fcr die Graduierung wurden keine Symbole verwendet, die St\u00e4rke der \nEmpfehlung ergibt sich implizit aus der Syntax (soll/sollte/kann).   \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  9 \n2. Konsentierte  und abgestimmte \nEmpfehlungen  und Statements  \n \n2.1. Risikofaktoren  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n1. Tabakkonsum ist ein wesentlicher Risikofaktor f\u00fcr die Entwicklung des \nMundh\u00f6hlenkarzinoms.  St 2+ SIGN: (14) \n(15) (16) \n(17) (18) \n(19) (20) \n(21) (22) \n(23) \n2. Alkohol konsum ist ein wesentlicher Risikofaktor f\u00fcr die Entwicklung des \nMundh\u00f6hlenkarzinoms.  St 2+ SIGN: (24) \n(25) \n3. Die Adressaten dieser LL sollten ihre Patienten darauf hinweisen, den \nTabakkonsum aufzugeben und den Alkoholkonsum weitgehend zu \nreduzieren   GCP  \n4. Der Nachweis von HPV 16 im Serum ist assoziiert mit einem erh\u00f6hten \nRisiko f\u00fcr das Mundh\u00f6hlenkarzinom  St 2+ SIGN: (36) \n(8) \n \n2.2. Screening und Pr\u00e4vention  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n5. Die zahn\u00e4rztliche und \u00e4rztliche Untersuchung soll bei jedem Patienten eine \nInspektion der gesamten Mundschleimhaut beinhalten.   GCP  \n6. Die Aufkl\u00e4rung \u00fcber Anzeichen, Symptome und Risikofaktoren des \nMundh\u00f6hlenkarzinoms soll verbessert werden  A 1+ SIGN: (53) \n \n  Prim\u00e4rdiagnostik  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  10 \n2.3. Prim\u00e4rdiagnostik  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n7.  Alle Patienten mit einer mehr als zwei Wochen bestehenden unklaren \nSchleimhautver\u00e4nderung sollen unverz\u00fcglich zur Abkl\u00e4rung zu einem \nSpezialisten \u00fcberwiesen werden   GCP  \n8. Zum Ausschluss synchroner Zweittumore soll im Rahmen der \nPrim\u00e4rdiagnostik des Mundh\u00f6hlenkarzinoms  eine Hals -Nasen -\nOhren\u00e4rztliche Untersuchung, ggf. eine Endoskopie durchgef\u00fchrt werden   GCP  \n \n2.4. Bildgebende Verfahren und weitere Diagnostik  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n9. Zur Festlegung der lokalen Ausdehnung eines Mundh\u00f6hlenkarzinoms  \nsollten  eine  CT oder MRT durchgef\u00fchrt werden  B 3 SIGN: (67) \n(68) (69) \n10. Um Verf\u00e4lschungen des Kontrastmittelverhaltens am Prim\u00e4rtumor zu \nvermeiden, sollte die Tumorbiopsie erst nach Durchf\u00fchrung der \nSchichtbildgebung erfolgen   GCP  \n11. Die Panorama -Schichtaufnahme geh\u00f6rt zur zahn\u00e4rztlichen Basisdiagnostik \nund sollte vor Beginn der spezifischen Tumortherapie vorliegen   GCP  \n12. Bei zu erwartenden Metallartefakten im Bereich der Mundh\u00f6hle sollte die \nMRT dem CT zur Beurteilung des Prim\u00e4rtumors vorgezogen werden   GCP  \n13. Es besteht widerspr\u00fcchliche und keine belastbare Evidenz f\u00fcr die \n\u00dcberlegenheit von CT oder MRT zur Beurteilung der Knocheninvasion durch \nKarzinome der Mundschleimhaut  St 3 de novo: \n(70) (71) \n14. Es besteht widerspr\u00fcchliche und keine belastbare Evidenz f\u00fcr die \n\u00dcberlegenheit der CT oder MRT zur Beurteilung der Ausdehnung des \nPrim\u00e4rtumors  St 3 SIGN: (67) \n(68) \nde novo: \n(70) (72) \n15. Es besteht keine gesicherte Evidenz f\u00fcr die h\u00f6he re Testg\u00fcte oder \nzus\u00e4tzlichen Nutzen der Cone Beam CT (Dental -CT)  gegen\u00fcber der \nPanorama -Schichtaufnahme zur Beurteilung der Knocheninvasion am \nUnterkiefer  \n \n \n \n St 3 de novo: \n(73) \n16. Die PET -CT hat keinen Stellenwert in der Prim\u00e4rdiagnostik der lokalen St 2+ de novo: Bildgebende Verfahren und Diagnostik zum Ausschluss synchroner Zweittumoren, Fernmetastasen, \nunbekannter Prim\u00e4rtumoren (CUP) und Rezidive  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  11 \nAusdehnung eines bekannten Mundh\u00f6hlenkarzinoms  (74) (75) \n(76) (77) \n(78) (79) \n(80) \n17. Zur Feststellung der  N-Kategorie  soll die gesamte Region von der \nSch\u00e4delbasis bis zur oberen Thoraxapertur mit der CT oder MRT untersucht \nwerden  A 2+ SIGN: (67) \n(91)  \nde novo: \n(87) (92) \n(93) (94) \n(89) \n18. Die diagnostische Spezifit\u00e4t des Lymphknotenstagings am Hals kann durch \ndie Ultraschall gest\u00fctzte Feinnadelbiopsie verbessert werden  St 2++ SIGN: (95) \n(96) (97) \n19. Die diagnostische Spezifit\u00e4t und Sensitivit\u00e4t des Lymphknotenstagings am \nHals kann durch das FDG -PET-CT verbessert werden  St 2+ de novo: \n(98) (99) \n(100) (92) \n(93) (88) \n(101) (75) \n(102) \n20. Es besteht keine belastbare Evidenz f\u00fcr die Eignung der SLN Biopsie als \nMethode zur Vermeidung einer elektiven Halslymphknotenausr\u00e4umung  St 3 de novo: \n(103) (104) \n(105) (106) \n(107) (108) \n \n2.5. Bildgebende Verfahren und Diagnostik zum \nAusschluss synchroner Zweittumoren, \nFernmetastasen, unbekannter Prim\u00e4rtumoren (CUP) \nund Rezidive  \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n21. Bei Patienten mit fortgeschrittenem Mundh\u00f6hlenkarzinom (Stadium   III, IV) \nsoll zum Ausschluss eines pulmonalen Tumorbefalls (Filia, Zweitkarzinom) \nein Thorax -CT durchgef\u00fchrt werden  A 3 SIGN: (125) \nde novo: \n(126) (127) \n(128) \n22. Im Rahmen der Prim\u00e4rdiagnostik kann eine abdominale \nUltraschallunter suchung durchgef\u00fchrt werden   GCP  \n23. Bei Patienten mit Rezidivverdacht im Bereich der Kopf -Hals Region kann, \nwenn dieser mit CT und/oder MRT nicht best\u00e4tigt oder ausger\u00e4umt werden \nkonnte, eine PET -CT durchgef\u00fchrt werden  0 3 SIGN: (129) \n(130)  \nde novo: \n(110) \n24. Bei Patienten mit Rezidivverdacht  im Bereich der Kopf -Hals Region kann \neine Sonographie der Kopf -Halsregion zur Begr\u00fcndung der Indikation \nweiterer Ma\u00dfnahmen indiziert sein   GCP  Biopsie und Histopathologi e \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  12 \n2.6. Biopsie und Histopathologie  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n25. Die Probeentnahme soll aus dem Randbereich des Tumors erfolgen und \nrepr\u00e4sentativ sein.  \nDem Pathologen sollen klinisch relevante Informationen mitgeteilt werden.  \nBei unklarem Befund soll die Biopsie  wiederholt werden.  \nVor einer Re - Biopsie sollte R\u00fccksp rache mit dem Pathologen gehalten \nwerden.  \n \nDer histopathologische Befund soll umfassen:  \nTumorlokalisation, makroskopische Tumorgr\u00f6\u00dfe, histologischer Tumottyp \nnach WHO, histologischer Tumorgrad, Invasionstiefe, Lymphgef\u00e4\u00dfinvasion, \nBlutgef\u00e4\u00dfinvasion und perineurale Invasion, lokal infiltrierte Strukturen, \nKlassifikation pT, Angaben  befallenen Bezirken und infiltrierten Strukturen, \nR-Status.   A 2++ SIGN: (139) \n(140) (141) \n(142) (143) \n(144) (145) \n(146) (147) \n(148) (149) \n(150) (151) \n(152) (153) \n(154) (155) \n(156) \n26. Um einen positiven Resektionsrand, der mit einer schlechteren Prognose \nverbunden ist zu vermeiden, kann die Technik einer intraoperativen \nSchnellschnitthistologie hilfreich sein.   GCP  \n27. Histologisch sollte der Abstand vom Resektatrand  zum Prim\u00e4rtumor am \nFormalin -fixierten Pr\u00e4parat mindestens 3 -5 mm betragen.  \nDer orientierende Wert f\u00fcr die Resektion betr\u00e4gt 10 mm vom tastbaren \nTumorrand   GCP  \n28. Der histopathologische Befund soll in Kommunikation mit dem Kliniker die \ngenaue Lokalisat ion einer ggf. vorliegenden R+ -Situation beschreiben.  \nDas Tumorpr\u00e4parat soll mit klarer Bezeichnung der anatomischen \nTopographie an den Pathologen geschickt werden. Hierzu kann eine Faden - \noder Farbmarkierung erfolgen.   GCP  \n29. Der histopathologische  Befund des Neck -dissection  Pr\u00e4parates soll die  \nHalsseite, die Art der Neck -dissection, die ausger\u00e4umten Level, die \nGesamtanzahl der Lymphknoten mit Anzahl der befallenen Lymphknoten, \ndie Level der befallenen Lymphknoten,  den Durchmesser des gr\u00f6\u00dften \nbefallenen Lymphknoten, zus\u00e4tzlich entfernte Strukturen und falls \nvorhanden ein kapsel\u00fcberschreitendes Wachstum beinhalten.  A 2++ SIGN: (68) \n(140) (165) \n(166) (167) \n(168) (169) \n(170) (171) \n \n \n \n \n \n \n Behandlungsempfehlungen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  13 \n2.7. Behandlungsempfehlungen  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n30. Die Behandlung des Mundh\u00f6hlenkarzinoms soll interdisziplin\u00e4r nach \nAbstimmung jedes individuellen Falls innerhalb von Tumorboards unter \nBeteiligung der Fachdisziplinen Mund -, Kiefer - und Gesichtschirurgie, Hals -\nNasen -Ohrenheilkunde, Strahlentherapie, Onkolo gie, Pathologie und \nRadiologie durchgef\u00fchrt werden.   GCP  \n31. Der Patient soll ausf\u00fchrlich und mehrfach \u00fcber seine Erkrankung, \nBehandlungsm\u00f6glichkeiten und Folgest\u00f6rungen informiert werden   GCP  \n32. Patienten mit einem Mundh\u00f6hlenkarzinom sollten zur Feststellung des \nZahnstatus  vor Behandlungsbeginn durch einen erfahrenen Zahnarzt \nuntersucht werden.  B 3 SIGN: (181) \n(182) \n33. Sofern der Allgemeinzustand des Patienten es zul\u00e4sst, sollte bei kurativ \nresektablen Mundh\u00f6hlenkarzinomen die Operation, ggf. in Kombina tion \nmit einer sofortigen Rekonstruktion, durchgef\u00fchrt werden. Bei \nfortgeschrittenen Karzinomen sollte zus\u00e4tzlich eine postoperative Therapie \nerfolgen.  B 3 SIGN: (183) \n(184) (185) \n(186) \n \n \n2.8. Chirurgische Behandlung des Prim\u00e4rtumors  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n34. Die Therapie des Mundh\u00f6hlenkarzinoms soll die individuelle Situation des \nPatienten ber\u00fccksichtigen. Eine Entscheidung zur chirurgischen Therapie \nsoll unter Ber\u00fccksichtigung der Erreichbarkeit tumorfreier \nResekti onsgrenzen und der postoperativen Lebensqualit\u00e4t getroffen \nwerden.  A 3 SIGN: (153) \n(159) (207) \n(161) (162) \n(163) (164) \n(208) \n35. Im Falle eines mikroskopisch verbliebenen Tumorrestes (verfehlte R0 -\nResektion) sollte eine gezielte Nachresektion erfolgen, um die Prognose \ndes Patienten zu verbessern.  B 3 SIGN: (152) \n36. Die Kontinuit\u00e4t des Unterkiefers sollte bei der Tumorresektion erhalten \nbleiben, sofern weder in der Bildgebung noch intraoperativ ein Nachweis \neiner Tumorinvasion in den Knochen erbracht werden konnte.  B 3 SIGN: (209) \n(210) (211) \nde novo: \n(212) (213) \n(214) \n \n Halslymphknotenausr\u00e4umung  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  14 \n2.9. Halslymphknotenausr\u00e4umung  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n37. Beim Mundh\u00f6hlenkarzinom kommt es in 20 -40% zu einer okkulten \nMetastasierung in die Halslymphknoten. Nahezu immer sind dabei die Level \nI-III, nur sehr selten das Level V betroffen  St 3 SIGN: (172) \n(140) (223) \n(224) (225) \n(226) (227) \n(228) (229) \n(230) (231) \n(219) (232) \n(233) (234) \n(235) \n38. Liegt ein klinisch unauff\u00e4lliger Lymphknotenstatus vor (cN0), so \nunterscheiden sich die Ergebnisse der selektiven Neck -dissection (Level I -III) \nnicht von d enen der modifizierten radikalen oder radikalen Neck -dissection  St 3 SIGN: (223) \n(234) (236) \n(237) (238) \n(239) (240) \n(241) (242) \n(243) (244) \n39. Bei Patienten mit klinisch unauff\u00e4lligem Lymphknoten status (cN0) soll \nunabh\u00e4ngig von  der T-Kategorie  eine elektive Neck -dissection durchgef\u00fchrt \nwerden  A 3 SIGN: (234) \n(245) (246) \n(247) (248) \n(249) (250) \n(251) (252) \nde novo: \n(253) (254) \n \n \n \n \n \n \n \n \n \n \n \n \n Halslymphknotenausr\u00e4umung  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  15 \nGem\u00e4\u00df der g\u00e4ngigen Klassifikation nach Robbins werden folgende sechs Lymphknotenlevel \nunterschieden, die bei der Neck -dissection ausger\u00e4umt werden k\u00f6nnen (s. Anhang 2) (256): \n \nLevel  Bezeichnung  anatomische Begrenzung  \nIA und \nIB Submentale  Knoten und \nsubmandibul\u00e4re Knoten  ventral und \ndorsal des vorderen Digastrikusbauches  \nIIA und \nII B obere jugul\u00e4re Lymphknotengruppe  Ventral  und \ndorsal der V. jugularis  \nIII mittlere jugul\u00e4re  Lymphknotengruppe  Zwischen H\u00f6he des Zungenbeins und          \nMembrana cricothyroidea  \nIV untere jugul\u00e4re Lymphknotengruppe  Zwischen H\u00f6he der Membrana cricothyroidea  und \nClavicula  \nVA und \nVB hinteres Halsdreieck  zwischen SCM und Trapezius  \noberhalb und unterhalb  des Omohyoideus  \nVI anteriore pr\u00e4tracheale Lymphknotengruppe  zwischen H\u00f6he des Hyoids und Jugulum  \n \nAbh\u00e4ngig von der Intention spricht man von einer elektiven (prophylaktischen) Neck -\ndissection, wenn ein cN0 - Befund vorliegt und einer kurativen Neck -dissection, wenn sich \naufgrund der klinischen und radiologischen Voruntersuchungen der Verdacht auf das \nVorliegen einer oder mehrerer Lymphknotenmetastasen ergeben hat. Bez\u00fcglich des \nAusma\u00dfes der Neck -dissection werden folgende Modifikationen unterschieden  (139) (256): \n Radikale Neck -dissection    Ausr\u00e4umung der Level I -V zusammen mit \n                 Opferung des N. accessorius, der V. jugularis \n                  und des M. sternocleidomastoideus  \n Modifizierte radikale Neck -dissection  Ausr\u00e4umung der Level I -V unter Erhalt einer \n      oder mehrerer nicht -lymphatischer Strukturen  \nSelekti ve Neck -dissection    Ausr\u00e4umung von weniger Levels als I -V; beim \n      Mundh\u00f6hlenkarzinom in der Regel  \n      Ausr\u00e4umung der Level I -III \nErweiterte Neck -dissection    Ausr\u00e4umung oder Entfernung zus\u00e4tzlicher \n      Lymphknotengruppen oder nicht - \n      lymphat ischer Strukturen  \n \n \n \n \n Rekonstruktion  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  16 \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n40. Der Erhalt des N. accessorius bei der Neck -dissection f\u00fchrt zu einer \nVerbesserung der Lebensqualit\u00e4t  St 3 de novo: \n(272) (273) \n41. Die Ergebnisse einer modifizerten radikalen Neck -dissection k\u00f6nnen in \nausgew\u00e4hlten F\u00e4llen bei bereits eingetretener Metastasierung mit denen \neiner radikalen Neck -dissection gleichwertig sein  St 3 SIGN: (241) \n(274) (275) \n(276) (277) \n(278) (279)   \nde novo: \n(280) (281) \n(282) \n42. Die Ergebnisse einer selektiven Neck -dissection  (Level I -III)  in Kombination \nmit einer postoperativen Radiochemotherapie k\u00f6nnen in ausgew\u00e4hlten \nF\u00e4llen bei bereits eingetretener Lymphknotenmetastasierung denen einer \nmodifizierten radikalen Neck -dissection mit postoperativer Radiotherapie  \ngleichwertig s ein St 3 SIGN: (283) \n(284)  \nde novo: \n(285) \n43. Liegt klinisch ein Verdacht auf Lymphknotenbefall vor (cN+), soll eine \nangemessene Halslymphknotenausr\u00e4umung, in der Regel eine modifizierte \nradikale Neck -dissection vorgenommen werden  A 3 SIGN: (226) \n(241) (243) \n(274) (275) \n(276) (276) \n(277) (278) \n(279)  \nde novo: \n(280) (281) \n(282) \n \n2.10.  Rekonstruktion  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n44. Rekonstruktive  Ma\u00dfnahmen sollen grunds\u00e4tzlich Teil eines chirurgischen \nKonzeptes sein. Die Planung der Rekonstruktion soll unter \nBer\u00fccksichtigung der onkologischen Gesamtsituation erfolgen. Der \nAufwand der Rekonstruktion soll durch die zu erwartende funktionelle oder \n\u00e4sthetische Verbesserung gerechtfertigt werden  A 3 SIGN: (300) \n(301) (302) \n45. Die Rekonstruktion im Bereich der Mundh\u00f6hle mit mikrochirurgisch \nanastomosierten Transplantaten stellt eine bew\u00e4hrte Methode dar. In vielen \nF\u00e4llen ist die Technik des mikrovaskul\u00e4ren Gewebetransfers bereits  im \nRahmen der Tumorresektion indiziert, um eine sichere Defektdeckung zu \nerreichen  St 3 SIGN: (303) \n(304) (305) \n(306) (307) \n(300) (308) \n(309) (301) \n(310) (302) \n \n Strahlentherapie  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  17 \n2.11.  Strahlentherapie  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n46. Eine Unterbrechung der Strahlentherapie f\u00fchrt zu einer Verschlechterung \nder Tumorkontrolle und soll vermieden werden  A 2+ SIGN: (311) \n(312) (313) \n47. Bei einer alleinigen prim\u00e4ren perkutanen Bestrahlung sollte eine alternative \nFraktionierung (Hyperfraktionierung/ Akzelerierung) gew\u00e4hlt werden   GCP  \n \n \n2.12.  Strahlentherapie in Kombination mit Chemotherapie  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n48. Eine neoadjuvante oder adjuvante  Chemotherapie hat beim \nPlattenepithelkarzinom der Mundh\u00f6hle in Verbindung mit der Operation \nkeinen positiven Effekt  St 1++ SIGN: (343) \n(344) (160) \n49. Bei einer simultanen prim\u00e4ren Radiochemotherapie  sollte die \nChemotherapie mit Cisplatin oder einer Cisplatin -haltigen Kombination  \nerfolgen   GCP  \n50. Bei Patienten mit fortgeschrittenem, nicht operablem und nicht \nmetastasiertem Mundh\u00f6hlenkarzinom soll, besonders in den Altersgruppen \nbis 70 Jahren, eine prim\u00e4re Radiochemotherapie einer alleinigen \nStrahlentherapie vorgezogen werden  A 1++ SIGN: (343) \n(344) \n51. Eine Radioche motherapie soll  nur an Einrichtungen stattfinden, an denen \nStrahlen - oder Chemotherapie bedingte akute Toxizit\u00e4ten erkannt und \nad\u00e4quat behandelt werden k\u00f6nnen   GCP  \n52. Alternativ zu einer Radiochemotherapie kann eine Kombination der \nStrahlentherapie mit Cetuximab durchgef\u00fchrt werden.   GCP  \n53. Eine postoperative Radio - oder Radiochemothe rapie soll bei \nfortgeschrittener  T-Kategorie  (T3/T4), knappen oder positiven \nResektionsr\u00e4ndern, perineuraler Invasion, Gef\u00e4\u00dfinvasion und/oder \nLymphknotenbefall erfolgen  A 1++ SIGN: (239) \n(292) (364) \n(365) (366) \n(367) (293) \n(294) \n54. Die postoperative Strahlentherapie soll  konventionell fraktioniert werden \nund bei durchschnittlichem Risiko mit 54 -60 Gy  in 27 -30 Fraktionen \u00fcber \n5,5-6 Wochen sowie bei Tumoren mit erh\u00f6htem Rezidivrisiko mit 66 Gy in \n33 Fraktionen \u00fcber 6,5 Wochen erfolgen  \n \n A 1++ SIGN: (367) \n(293) (294) \n(368) Pr\u00e4vention und Behandlung strahlenbedingter Begleiterscheinungen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  18 \n55. Die postoperative Strahlentherapie sollte m\u00f6glichst fr\u00fch begonnen werden \nund   innerhalb eines Zeitraums von h\u00f6chstens 11 Wochen nach der \nOperation beendet werden  B 2++ SIGN: (369) \n(370) \n56. Sofern die Indikation zu einer Radiotherapie gestellt wurde, sollte bei \nPatienten mit erh\u00f6hten histopathologischen Risikokriterien f\u00fcr ein \nTumorrezidiv (Resektionsrand <5mm und/oder extrakapsul\u00e4res \nTumorwachstum) nach erfolgter Tumorresektion  die adju vante Behandlung \nin Form einer Radiochemotherapie mit Cisplatin erfolgen  B 2++ SIGN: (371) \n(367) (293) \n(294) (372) \n(373) \n57. Patienten mit kleinen und zug\u00e4nglichen Tumoren (T1 / T2) der Mundh\u00f6hle \nk\u00f6nnen in ausgew\u00e4hlten F\u00e4llen durch eine interstitielle Brachytherapie \nbehandelt werden.  0 3 SIGN: (331) \n(216) (335) \n(337) \n \n \n2.13.  Pr\u00e4vention und Beh andlung strahlenbedingter \nBegleiterscheinungen  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n58. Es bestehen Hinweise daf\u00fcr, dass mit der intensit\u00e4tsmodulierten \nStrahlentherapie (IMRT) die  H\u00e4ufigkeit und der Schweregrad einer \nstrahleninduzierten Xerostomie reduziert werden k\u00f6nnen  St 3 SIGN: (327) \n59. Patienten, die wegen eines Karzinoms im Bereich der Mundh\u00f6hle bestrahlt \nwerden, sollen eine optimale Zahn - und Mundpflege erhalten   GCP  \n60. Patienten sollen vor der Durchf\u00fchrung einer Radio/ Radiochemotherapie im \nBereich der Mundh\u00f6hle zur Vermeidung einer Osteoradionekrose eine \nzahn\u00e4rztliche Untersuchung und ggf. eine konservierende und/oder \nchirurgische Zahnsanierung erhalten   GCP  \n61. Zu Be ginn einer Strahlentherapie im Bereich der Mundh\u00f6hle soll eine \nFluoridierungsschiene und bei Bedarf eine Distanzschiene angefertigt \nwerden   GCP  \n62. Patienten, die wegen eines Karzinoms im Bereich der Mundh\u00f6hle bestrahlt \nwurden, sollte bei erhaltener Restfunktion der Speicheldr\u00fcsen dreimal \nt\u00e4glich Pilocarpin oral angeboten werden, sofern keine Kontraindikationen \nvorliegen  B 1+ SIGN: (387) \n(388) \n \n \n \n Behandlung des lokoregion\u00e4ren Rezidivs  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  19 \n2.14.  Behandlung des lokoregion\u00e4ren Rezidivs  \n \n  \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n63. Eine Salvage -Operation sollte bei allen Patienten mit einem resektablen \nlokoregion\u00e4ren Rezidiv nach vorausgegangener Strahlentherapie oder \nOperation in Erw\u00e4gung gezogen werden. Der Eingriff sollte nur durch ein \nerfahrenes chirurgisches Team mit umfangreichen M\u00f6glichkeiten der \nRekonstruktion und in einer Einrichtung mit einer g eeigneten \nintensivmedizinischen Einrichtung durchgef\u00fchrt werden.  B 3 SIGN: (412) \n(413) \n64. Bei bereits bestrahlten Patienten mit einem nicht -resektablen \nlokoregion\u00e4ren  Rezidiv sollte eine Zweitbestrahlung mit ggf. kurativer \nIntention in Betracht gezogen werden.  Die Bestrahlung sollte nur in einer \nEinrichtung mit ad\u00e4quater Expertise und idealer - weise innerhalb einer \nklinischen Therapiestudie erfolgen  B 3 SIGN: (414) \n(415) (416) \n(417) (418) \n(419) \n \n \n2.15.  Palliative und palliativmedizinische Behandlung  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n65. Patienten mit einem unheilbaren Tumorleiden, jedoch einem guten \nAllgemein - und Leistungszustand sollen einer palliativen platinbasierten \nChemotherapie in Kombination mit Cetuximab zugef\u00fchrt werden. Bei \nPatienten mit reduziertem Allgemeinzustand sollte eine  Monotherapie \nerwogen werden. Eine exzessive Toxizit\u00e4t durch eine Kombinations -\nChemotherapie sollte vermieden werden.   GCP  \n66. Bei Patienten mit einem inkurablen Mundh\u00f6hlemkarzinom kann eine \npalliative Strahlentherapie in Erw\u00e4gung gezogen werden.  0 3 SIGN: (422) \n67. Bei Patienten mit einem inkurablen Mundh\u00f6hlenkarzinom k\u00f6nnen palliative \nchirurgische und/oder radiologisch -interventionelle Ma\u00dfnahmen zur \nVerbesserung Tumor -assoziierter Komplikationen in Erw\u00e4gung gezogen \nwerden  0 3 SIGN: (423) \n(424) (425) \n(426) (427) \n(428) \n \n \n Nachsorge und Rehabilitation  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  20 \n2.16.  Nachsorge und Rehabilitation  \n2.16.1.  Nachsorge  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n68. Als maximale Nachsorgeintervalle sollten auch bei Beschwerdefreiheit f\u00fcr \ndas 1. und 2. Jahr 3 Monate und das 3. bis 5. Jahr 6 Monate eingehalten \nwerden. F\u00fcr jeden Patienten sollte ein strukturierter individueller \nNachsorgeplan erstellt werden. Die Lebensqualit\u00e4t der Patienten sollte in \nregelm\u00e4\u00dfigen Abst\u00e4nden erfragt werden. Nach dem 5. Jahr sollten die \n\u00fcblichen Fr\u00fcherkennungsma\u00dfnahmen zur Anwendung kommen.   GCP  \n \n \n2.16.2.  Kaufunktionelle Rehabilitation  \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n69. Patienten, die wegen eines Mundh\u00f6hlenkarzinoms operiert und/oder \nbestrahlt worden sind sollten eine Wiederherstellung ihrer Kauf\u00e4higkeit \ndurch eine kaufunktionelle Rehabilitation durch Implantat - bzw. \nkonventionell prothetische Versorgung erhalten. Weiterhin sollte bei diesen \nPatienten eine regelm\u00e4\u00dfige zahn\u00e4rztliche \u00dcberwachung erfolgen. \nZahn\u00e4rztlich -chirurgische Ma\u00dfnahmen sollten bei diesen Patienten durch \nmit diesem Krankheitsbild erfahrenen Fachkollegen vorgenommen werden.  B 3 SIGN: (181) \n(182) (449) \n(450) (451) \n(452) \n70. Die infizierte Osteoradionekrose der Kiefer stellt eine schwerwiegende \nBehandlungskomplikation dar. Es besteht keine Evidenz f\u00fcr einen Effekt \neiner alleinigen hyperbar en Sauerstofftherapie zur Prophylaxe oder \nBehandlung dieser Komplikation. Die hyperbare Sauerstofftherapie kann in \nVerbindung mit chirurgischen Ma\u00dfnahmen zur Prophylaxe oder Behandlung \neiner Osteoradionekrose sinnvoll sein.  St 3 SIGN: (219) \n(220) (389) \n(455) (456) \n(457) (458) \n \n \n2.16.3.  Sprech - und Schluckrehabilitation  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n71. Patienten mit Kau -, Sprech - und Schluckst\u00f6rungen sollten eine ad\u00e4quate \nfunktionelle Therapie erhalten. Die  Patienten sollten bereits vor \nBehandlungsbeginn bei entsprechend qualifizierten Therapeuten vorgestellt \nwerden, wenn als Folge der geplanten chirurg ischen oder konservativen B 2+ SIGN: (462) \n(463) (464) \n(465) (466) \n(467) Nachsorge und Rehabilitation  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  21 \nMa\u00dfnahmen Kau -, Schluck - und/oder Sprechst\u00f6rungen zu erwarten sind.  \n72. Patienten mit einer Dysphagie  sollten  einer ad\u00e4quaten Diagnostik, z.B. \neiner hochfrequenten Fluroskopie mit Kontrastmittel oder einer \nfiberoptischen Endoskopie zugef\u00fchrt werden.  B 2+ SIGN: (465) \n(466) \n73. Patienten, die wegen eines Mundh\u00f6hlenkarzinoms Probleme bei der \nNahrungsaufnahme und beim Sprechen haben und/oder eine \nRadio/Radiochemotherapie erhalten sollten vor, w\u00e4hrend und nach der \nBehandlung Zugang zu einem mit diesem Kra nkheitsbild erfahrenen \nLogop\u00e4den haben  B 2+ SIGN: (468) \n \n \n2.16.4.  Ern\u00e4hrungstherapie  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n74. Patienten, die tumor - oder behandlungsbedingt dem Risiko einer \nMalnutrition ausgesetzt sind, sollten fr\u00fchzeitig eine professionelle \nErn\u00e4hrungsberatung und Ern\u00e4hrungstherapie erhalten  B 2+ SIGN: (472) \n(473) (474) \n(475) (476) \n(477) \n \n \n2.16.5.  Psychosoziale Beratung und Betreuung  \n \nNr. Empfehlungen/Statements  EG LoE \n Quellen  \n75. Patienten mit einem Mundh\u00f6hlenkarzinom soll eine psychosoziale \nBetreuung  durch Sozialarbeiter  angeboten werden   GCP  \n76. Zur Gew\u00e4hrleistung einer Kontinuit\u00e4t der psychoonkologischen Betreuung \nnach der station\u00e4ren Behandlung sollen Patienten mit einem \nMundh\u00f6hlenkarzinom \u00fcber weiterf\u00fchrende ambulante und nachsorgende \nAngebote informiert werden (Krebsberatungsstellen, niedergelasse n \nPsychotherapeuten, Selbsthilfegruppen, Sozialberatung)   GCP  \n Qualit\u00e4tsindikatoren  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  22 \n3. Qualit\u00e4tsindikatoren  \n \nQualit\u00e4tsindikatoren , die gem\u00e4\u00df einer standardisierten Methodik von den starken (A) \nEmpfehlungen dieser Leitlinie abgeleitet wurden, finden sich in der Langversion dieser \nLeitlinie.  \nQI \nNr. Z\u00e4hler / Nenner  Referenz \nEmpfehlung  Quellen  \n1. Z:  \nAnzahl Patienten mit Hals -Nasen -Ohren\u00e4rztlicher Untersuchung \nzum Ausschluss synchroner Zweittumore  \nN:  \nAlle Patienten mit Prim\u00e4rdiagnostik eines Mundh\u00f6hlenkarzinoms  Nr. 8   GCP \n2. Z:  \nAnzahl Patienten mit Untersuchung der Region von der \nSch\u00e4delbasis bis zur oberen Thoraxapertur mit CT oder MRT zur \nFeststellung der N -Kategorie  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarzinom   Nr. 17   Leitlinienadaptatio\nn SIGN: (67) (91); \nde novo: (87) (92) \n(93) (94) (89) \n3. Z:  \nAnzahl Patienten mit Thorax CT zum Ausschluss pulmonalen \nTumorbefalls (Filia, Zweitkarzinom)  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarzinom Stadium III + IV  Nr. 21  Leitlinienadaptatio\nn SIGN: (125); de \nnovo: (126) (127) \n(128) \n4. Z:  \nAnzahl Patienten, bei denen der histopathologische Befund wie \nfolgt dokumentiert ist: Tumorlokalisation, makroskopische \nTumorgr\u00f6\u00dfe, histologischer Tumortyp  nach WHO, histologischer \nTumorgrad, Invasionstiefe, Lymphgef\u00e4\u00df -invasion, Blutgef\u00e4\u00dfinvasion \nund perineurale Invasion, lokal infiltrierte Strukturen, Klassifikation \npT, Angaben  befallenen Bezirken und infiltrierten Strukturen, R -\nStatus.  \nN:  \nAlle Patienten  mit Mundh\u00f6hlenkarzinom  und Operation  Nr. 28  Leitlinienadaptatio\nn SIGN: (139) (140) \n(141) (142) (143) \n(144) (145) (146) \n(147) (148) (149) \n(150) (151) (152) \n(153) (154) (155) \n(156) \n5. Z:  \nAnzahl Patienten mit interdisziplin\u00e4rer Behandlung nach \nAbstimmung in Tumorboards unter Beteiligung der Fachdisziplinen \nMund -, Kiefer - und Gesichtschirurgie, Hals -Nasen -Ohrenheilkunde, \nStrahlentherapie, Onkologie, Pathologie und Radiologie  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarzinom  Nr. 30  GCP \n6. Z:  \nAnzahl Patienten mit elektiver Neck -Dissection  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarzinom und cNO jeglicher T -\nKategorie  \n Nr. 39  Leitlinienadaptatio\nn SIGN: (234) (245) \n(246) (247) (248) \n(249) (250) (251) \n(252); de novo: \n(253) (254) Qualit\u00e4tsindikatoren  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  23 \n7. Z:  \nAnzahl Patienten ohne Unterbrechung der Strahlentherapie  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarzinom und Strahlentherapie  \n Nr. 46  Leitlinienadaptatio\nn SIGN: (311) (312) \n(313) \n8. Z:  \nAnzahl Patienten mit postoperativer Radio - oder \nRadiochemotherapie  \nN:  \nAlle Patienten mit T3/T4 -Kategorie, knappen oder positiven \nResektionsr\u00e4ndern, perineuraler oder Gef\u00e4\u00dfinvasion oder LK+  Nr. 53  Leitlinienadaptatio\nn SIGN: (239) (292) \n(364) (365) (366) \n(367) (293) (294) \n9. Z:  \nAnzahl Patienten mit  zahn\u00e4rztlicher Untersuchung vor Beginn der \nRadio - oder Radiochemotherapie  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarziom und Radio -  oder \nRadiochemo -therapie  Nr. 60  GCP \n10. Z:  \nAnzahl Patienten mit dokumentiertem Angebot einer \npsychosozialen Betreuung durch einen Sozialarbeiter  \nN:  \nAlle Patienten mit Mundh\u00f6hlenkarzinom  Nr. 75  GCP \n \n  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  24 \n4. Referenzen  \n \n1. Lippman SM, Spitz M, Trizna Z, Benner SE, Hong WK. Epidemiology, biology, and chemoprevention of aerodigestive cancer. \nCancer. 1994;74(9 Suppl):2719 -25. Epub 1994/11/01.  \n2. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID) in Zusammenarbeit mit dem Robert Koch \nInstitut: 5. \u00fcberarbeitete, aktualisierte Ausg abe. Saarbr\u00fccken 2006.  \n3. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: \nfactors affecting survival. J Oral Maxillofac Surg. 2003;61(7):751 -8. Epub 2003/07/12.  \n4. Howaldt HP, Vorast H, Blecher JC, Reicherts M, Kainz M. Ergebnisse aus dem D\u00d6SAK Tumorregister. Mund Kiefer \nGesichtschir. 2000;4 Suppl 1:S216 -25. Epub 2000/08/12.  \n5. Talamini R, Bosetti C, La Vecchia C, Dal Maso L, Levi F, Bidoli E, et al. Combined effect of tobacco and alcohol  on laryngeal \ncancer risk: a case -control study. Cancer causes & control : CCC. 2002;13(10):957 -64. Epub 2003/02/18.  \n6. La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E. Epidemiology and prevention of oral cancer. Oral Oncol. \n1997;33(5):302 -12. Epub 1998/02/12.  \n7. Figuero Ruiz E, Carretero Pelaez MA, Cerero Lapiedra R, Esparza Gomez G, Moreno Lopez LA. Effects of the consumption \nof alcohol in the oral cavity: relationship with oral cancer. Medicina oral : organo oficial de la Sociedad Espanol a de Medicina Oral y \nde la Academia Iberoamericana de Patologia y Medicina Bucal. 2004;9(1):14 -23. Epub 2004/01/06.  \n8. Cruz GD, Le Geros RZ, Ostroff JS, Hay JL, Kenigsberg H, Franklin DM. Oral cancer knowledge, risk factors and \ncharacteristics of subjects in a large oral cancer screening program. J Am Dent Assoc. 2002;133(8):1064 -71; quiz 94. Epub \n2002/08/30.  \n9. Hay JL, Ostroff JS, Cruz GD, LeGeros RZ, Kenigsberg H, Franklin DM. Oral cancer risk perception among participants in an \noral cancer screening prog ram. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for \nCancer Research, cosponsored by the American Society of Preventive Oncology. 2002;11(2):155 -8. Epub 2002/02/28.  \n10. Horowitz AM, Canto MT, Child WL. Maryland adults' perspectives on oral cancer prevention and early detection. J Am Dent \nAssoc. 2002;133(8):1058 -63. Epub 2002/08/30.  \n11. Warnakulasuriya KA, Harris CK, Scarrott DM, Watt R, Gelbier S, Peters TJ, et al. An alarming lack of public awareness \ntowards ora l cancer. British dental journal. 1999;187(6):319 -22. Epub 1999/12/10.  \n12. Vora AR, Yeoman CM, Hayter JP. Alcohol, tobacco and paan use and understanding of oral cancer risk among Asian males \nin Leicester. British dental journal. 2000;188(8):444 -51. Epub 2 000/08/23.  \n13. Scottish Intercollegiate Guidelines Network SIGN 90: Diagnosis and management of head and neck cancer. 2006.  \n14. Altieri A, Bosetti C, Talamini R, Gallus S, Franceschi S, Levi F, et al. Cessation of smoking and drinking and the risk of \nlaryn geal cancer. Br J Cancer. 2002;87(11):1227 -9. Epub 2002/11/20.  \n15. Balaram P, Sridhar H, Rajkumar T, Vaccarella S, Herrero R, Nandakumar A, et al. Oral cancer in southern India: the \ninfluence of smoking, drinking, paan -chewing and oral hygiene. Internation al journal of cancer Journal international du cancer. \n2002;98(3):440 -5. Epub 2002/03/29.  \n16. Cheng YJ, Hildesheim A, Hsu MM, Chen IH, Brinton LA, Levine PH, et al. Cigarette smoking, alcohol consumption and risk \nof nasopharyngeal carcinoma in Taiwan. Cance r causes & control : CCC. 1999;10(3):201 -7. Epub 1999/08/24.  \n17. De Boer MF, Van den Borne B, Pruyn JF, Ryckman RM, Volovics L, Knegt PP, et al. Psychosocial and physical correlates of \nsurvival and recurrence in patients with head and neck carcinoma: resul ts of a 6 -year longitudinal study. Cancer. 1998;83(12):2567 -\n79. Epub 1999/01/05 21:59.  \n18. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as \nprognostic indicators in head and neck cancer.  Eur J Cancer. 2001;37(3):332 -9. Epub 2001/03/10.  \n19. De Stefani E, Boffetta P, Oreggia F, Mendilaharsu M, Deneo -Pellegrini H. Smoking patterns and cancer of the oral cavity and \npharynx: a case -control study in Uruguay. Oral Oncol. 1998;34(5):340 -6. Epub 1 998/12/23.  \n20. Franceschi S, Levi F, La Vecchia C, Conti E, Dal Maso L, Barzan L, et al. Comparison of the effect of smoking and alcohol \ndrinking between oral and pharyngeal cancer. International journal of cancer Journal international du cancer. 1999;83(1 ):1-4. Epub \n1999/08/17.  \n21. Lissowska J, Pilarska A, Pilarski P, Samolczyk -Wanyura D, Piekarczyk J, Bardin -Mikollajczak A, et al. Smoking, alcohol, diet, \ndentition and sexual practices in the epidemiology of oral cancer in Poland. Eur J Cancer Prev. 2003;1 2(1):25 -33. Epub 2003/01/28.  \n22. Perea -Milla Lopez E, Minarro -Del Moral RM, Martinez -Garcia C, Zanetti R, Rosso S, Serrano S, et al. Lifestyles, environmental \nand phenotypic factors associated with lip cancer: a case -control study in southern Spain. Br J Cancer. 2003;88(11):1702 -7. Epub \n2003/05/29.  \n23. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax. 2003;58(5):435 -43. \nEpub 2003/05/03.  \n24. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumpt ion and the risk of cancer: a meta -analysis. Alcohol \nresearch & health : the journal of the National Institute on Alcohol Abuse and Alcoholism. 2001;25(4):263 -70. Epub 2002/03/26.  \n25. Corrao G, Bagnardi V, Zambon A, Arico S. Exploring the dose -response rel ationship between alcohol consumption and the \nrisk of several alcohol -related conditions: a meta -analysis. Addiction. 1999;94(10):1551 -73. Epub 2000/05/03.  \n26. Bosetti C, Gallus S, Trichopoulou A, Talamini R, Franceschi S, Negri E, et al. Influence of the Mediterranean diet on the risk \nof cancers of the upper aerodigestive tract. Cancer epidemiology, biomarkers & prevention : a publication of the American \nAssociation for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003;12(10 ):1091 -4. Epub \n2003/10/28.  \n27. Bosetti C, Talamini R, Levi F, Negri E, Franceschi S, Airoldi L, et al. Fried foods: a risk factor for laryngeal cancer? Br J  \nCancer. 2002;87(11):1230 -3. Epub 2002/11/20.  \n28. Levi F, Pasche C, Lucchini F, Chatenoud L, Jacobs DR, Jr., La Vecchia C. Refined and whole grain cereals and the risk of \noral, oesophageal and laryngeal cancer. European journal of clinical nutrition. 2000;54(6):487 -9. Epub 2000/07/06.  \n29. Oreggia F, De Stefani E, Boffetta P, Brennan P, Deneo -Pellegrini H , Ronco AL. Meat, fat and risk of laryngeal cancer: a case -\ncontrol study in Uruguay. Oral Oncol. 2001;37(2):141 -5. Epub 2001/02/13.  \n30. Bosetti C, La Vecchia C, Talamini R, Negri E, Levi F, Fryzek J, et al. Energy, macronutrients and laryngeal cancer risk.  Annals \nof oncology : official journal of the European Society for Medical Oncology / ESMO. 2003;14(6):907 -12. Epub 2003/06/11.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  25 \n31. Uzcudun AE, Retolaza IR, Fernandez PB, Sanchez Hernandez JJ, Grande AG, Garcia AG, et al. Nutrition and pharyngeal \ncancer: r esults from a case -control study in Spain. Head Neck. 2002;24(9):830 -40. Epub 2002/09/05.  \n32. Franceschi S, Favero A, Conti E, Talamini R, Volpe R, Negri E, et al. Food groups, oils and butter, and cancer of the oral \ncavity and pharynx. Br J Cancer. 1999;8 0(3-4):614 -20. Epub 1999/07/17.  \n33. De Stefani E, Oreggia F, Boffetta P, Deneo -Pellegrini H, Ronco A, Mendilaharsu M. Tomatoes, tomato -rich foods, lycopene \nand cancer of the upper aerodigestive tract: a case -control in Uruguay. Oral Oncol. 2000;36(1):47 -53. Epub 2000/07/13.  \n34. Bosetti C, La Vecchia C, Talamini R, Negri E, Levi F, Dal Maso L, et al. Food groups and laryngeal cancer risk: a case -control \nstudy from Italy and Switzerland. International journal of cancer Journal international du cancer. 2002;10 0(3):355 -60. Epub \n2002/07/13.  \n35. Tavani A, Pelucchi C, Parpinel M, Negri E, Franceschi S, Levi F, et al. n -3 polyunsaturated fatty acid intake and cancer risk in \nItaly and Switzerland. International journal of cancer Journal international du cancer. 2003; 105(1):113 -6. Epub 2003/04/03.  \n36. Dahlstrom KR, Adler -Storthz K, Etzel CJ, Liu Z, Dillon L, El -Naggar AK, et al. Human papillomavirus type 16 infection and \nsquamous cell carcinoma of the head and neck in never -smokers: a matched pair analysis. Clinical ca ncer research : an official \njournal of the American Association for Cancer Research. 2003;9(7):2620 -6. Epub 2003/07/12.  \n37. van der Waal I, Scully C. Oral cancer: comprehending the condition, causes, controversies, control and consequences. 6. \nCo-morbiditi es. Dental update. 2011;38(4):283 -4. Epub 2011/07/01.  \n38. Axell T. Hypersensitivity of the oral mucosa: clinics and pathology. Acta odontologica Scandinavica. 2001;59(5):315 -9. \nEpub 2001/10/30.  \n39. Macfarlane GJ, Boyle P, Scully C. Oral cancer in Scotland:  changing incidence and mortality. BMJ. 1992;305(6862):1121 -3. \nEpub 1992/11/07.  \n40. Department of Dental Services. Screening for oral cancer. London: Royal College of Surgeons of England. 1994.  \n41. British Dental Association. Opportunistic oral cancer scre ening. BDA occasional paper, April 2000 (issue number 6). [cited \n11 August 2006]. Available from url: http://www.bda -dentistry.org.uk/about/docs/mouth_cancer.pdf . \n42. Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, Lazarus P. The human OGG1 DNA repair enzyme and its association with \norolaryngeal cancer risk. Carcinogenesis. 2002;23(7):1229 -34. Epub 2002/07/16.  \n43. Elahi A, Bendaly J, Zheng Z, Muscat JE, Richie JP, Jr., Schantz SP, et  al. Detection of UGT1A10 polymorphisms and their \nassociation with orolaryngeal carcinoma risk. Cancer. 2003;98(4):872 -80. Epub 2003/08/12.  \n44. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for  squamous \ncell carcinoma of the head and neck. Cancer. 2002;94(2):393 -7. Epub 2002/03/20.  \n45. Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, et al. Cyclin D1 polymorphism and risk for squamous cell \ncarcinoma of the head and neck: a case -control  study. Carcinogenesis. 2001;22(8):1195 -9. Epub 2001/07/27.  \n46. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen -detoxifying enzyme UGT1A7 and its \nassociation with orolaryngeal cancer risk. Journal of the National Cancer Institute . 2001;93(18):1411 -8. Epub 2001/09/20.  \n47. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the \nInternational Agency for Research on Cancer multicenter study. Journal of the National Cancer I nstitute. 2003;95(23):1772 -83. Epub \n2003/12/05.  \n48. Pitiphat W, Diehl SR, Laskaris G, Cartsos V, Douglass CW, Zavras AI. Factors associated with delay in the diagnosis of oral \ncancer. Journal of dental research. 2002;81(3):192 -7. Epub 2002/03/06.  \n49. Jones  TM, Hargrove O, Lancaster J, Fenton J, Shenoy A, Roland NJ. Waiting times during the management of head and neck \ntumours. J Laryngol Otol. 2002;116(4):275 -9. Epub 2002/04/12.  \n50. Hollows P, McAndrew PG, Perini MG. Delays in the referral and treatment of o ral squamous cell carcinoma. British dental \njournal. 2000;188(5):262 -5. Epub 2000/04/12.  \n51. West Midlands Health Technology Assessment Collaboration (WMHTAC). The effectiveness of Toludine Blue Dye as an \nadjunct to oral cancer screening in general dental practice: Report 24. University of Birmingham: Department of Public Health & \nEpidemiology; 2000.  \n52. Kujan O, Glenny AM, Duxbury AJ, Thakker N, Sloan P. Screening programmes for the early detection and prevention of oral \ncancer. Cochrane Database Syst Rev.  2003(4):CD004150. Epub 2003/10/30.  \n53. Humphris GM, Freeman R, Clarke HM. Risk perception of oral cancer in smokers attending primary care: a randomised \ncontrolled trial. Oral Oncol. 2004;40(9):916 -24. Epub 2004/09/24.  \n54. Humphris GM, Ireland RS, Field E A. Randomised trial of the psychological effect of information about oral cancer in \nprimary care settings. Oral Oncol. 2001;37(7):548 -52. Epub 2001/09/21.  \n55. Humphris GM, Ireland RS, Field EA. Immediate knowledge increase from an oral cancer information l eaflet in patients \nattending a primary health care facility: a randomised controlled trial. Oral Oncol. 2001;37(1):99 -102. Epub 2000/12/20.  \n56. Chow T -L, Lee DT -Y, Choi C -Y, Chan TT -F, Lam S -H. Prediction of simultaneous esophageal lesions in head and neck  \nsquamous cell carcinoma: a multivariate analysis. Archives of Otolaryngology -- Head & Neck Surgery. 2009;135(9):882 -5. \n57. Fielding D, Agnew J, Wright D, Hodge R. Autofluorescence improves pretreatment mucosal assessment in head and neck \ncancer patients.  Otolaryngology - Head & Neck Surgery. 2010;142(3 Suppl 1):S20 -6. \n58. Kesting MR, Schurr C, Robitzky L, Steinstraesser L, Nieberler M, Baurecht H, et al. Results of esophagogastroduodenoscopy \nin patients with oral squamous cell carcinoma --value of endoscop ic screening: 10 -year experience. Journal of Oral & Maxillofacial \nSurgery. 2009;67(8):1649 -55. \n59. Kesting MR, Robitzky L, Al -Benna S, Steinstraesser L, Baurecht H, Wolff K -D, et al. Bronchoscopy screening in primary oral \nsquamous cell carcinoma: a 10 -year experience. British Journal of Oral & Maxillofacial Surgery. 2009;47(4):279 -83. \n60. Lee CT, Chang CY, Lee YC, Tai CM, Wang WL, Tseng PH, et al. Narrow -band imaging with magnifying endoscopy for the \nscreening of esophageal cancer in patients with primary h ead and neck cancers. Endoscopy. 2010;42(8):613 -9. \n61. Takenaka R, Kawahara Y, Okada H, Hori K, Inoue M, Kawano S, et al. Narrow -band imaging provides reliable screening for \nesophageal malignancy in patients with head and neck cancers. Am J Gastroenterol. 2009;104(12):2942 -8. \n62. Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer. 1992;70(1):14 -9. Epub 1992/07/01.  \n63. Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin -Harris B, et al. Oral cancer treatment. Current treatment o ptions in \noncology. 2003;4(1):27 -41. Epub 2003/01/15.  \n64. de Vries N, Van der Waal I, Snow GB. Multiple primary tumours in oral cancer. Int J Oral Maxillofac Surg. 1986;15(1):85 -7. \nEpub 1986/02/01.  \n65. Kramer FJ, Janssen M, Eckardt A. Second primary tumour s in oropharyngeal squamous cell carcinoma. Clinical oral \ninvestigations. 2004;8(2):56 -62. Epub 2004/03/17.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  26 \n66. Scottish Executive Health Department. Scottish Referral Guidelines for Suspected Cancer. Edinburgh: Scottish Executive \nHealth Department; 2002. [cited 11 August 2006]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/hdl2002_45.pdf . \n67. Wilson JA, editor. Effective head and neck cancer management: consensus document. Londo n: British Association of \nOtorhinolaryngologists, Head and Neck Surgeons; 1998.  \n68. Leslie A, Fyfe E, Guest P, Goddard P, Kabala JE. Staging of squamous cell carcinoma of the oral cavity and oropharynx: a \ncomparison of MRI and CT in T - and N -staging. J Com put Assist Tomogr. 1999;23(1):43 -9. Epub 1999/03/02.  \n69. Kaanders JH, Hordijk GJ. Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care \nand rehabilitation. Radiother Oncol. 2002;63(3):299 -307. Epub 2002/07/27.  \n70. Imaizumi A, Yoshino N, Yamada I, Nagumo K, Amagasa T, Omura K, et al. A potential pitfall of MR imaging for assessing \nmandibular invasion of squamous cell carcinoma in the oral cavity. AJNR Am J Neuroradiol. 2006;27(1):114 -22. \n71. Bolzoni A, Cappiello J,  Piazza C, Peretti G, Maroldi R, Farina D, et al. Diagnostic accuracy of magnetic resonance imaging in \nthe assessment of mandibular involvement in oral -oropharyngeal squamous cell carcinoma: a prospective study. Archives of \nOtolaryngology -- Head & Neck Su rgery. 2004;130(7):837 -43. \n72. Van Cann EM, Koole R, Oyen WJG, de Rooy JWJ, de Wilde PC, Slootweg PJ, et al. Assessment of mandibular invasion of \nsquamous cell carcinoma by various modes of imaging: constructing a diagnostic algorithm. International Journa l of Oral & \nMaxillofacial Surgery. 2008;37(6):535 -41. \n73. Hendrikx AWF, Maal T, Dieleman F, Van Cann EM, Merkx MAW. Cone -beam CT in the assessment of mandibular invasion \nby oral squamous cell carcinoma: results of the preliminary study. International Journal of Oral and Maxillofacial Surgery. 2010;39 \n(5):436 -9. \n74. Goerres GW, Schmid DT, Schuknecht B, Eyrich GK. Bone invasion in patients with oral cavity cancer: comparison of \nconventional CT with PET/CT and SPECT/CT.[Erratum appears in Radiology. 2006 Apr;239(1):303]. Radiology. 2005;237(1):281 -7. \n75. Yen T -C, Chang JT -C, Ng S -H, Chang Y -C, Chan S -C, Wang H -M, et al. Staging of untreated squamous cell carcinoma of \nbuccal mucosa with 18F -FDG PET: comparison with head and neck CT/MRI and histopathology. J  Nucl Med. 2005;46(5):775 -81. \n76. Hafidh MA, Lacy PD, Hughes JP, Duffy G, Timon CV. Evaluation of the impact of addition of PET to CT and MR scanning in \nthe staging of patients with head and neck carcinomas. European Archives of Oto -Rhino -Laryngology. 2006 ;263(9):853 -9. Epub \n2006/05/26.  \n77. Wax MK, Myers LL, Gona JM, Husain SS, Nabi HA. The role of positron emission tomography in the evaluation of the N -\npositive neck. Otolaryngol Head Neck Surg. 2003;129(3):163 -7. Epub 2003/09/06.  \n78. Krabbe CA, Dijkstra PU , Pruim J, van der Laan BFM, van der Wal JE, Gravendeel JP, et al. FDG PET in oral and oropharyngeal \ncancer. Value for confirmation of N0 neck and detection of occult metastases. Oral Oncology. 2008;44(1):31 -6. \n79. Nahmias C, Carlson ER, Duncan LD, Blodget t TM, Kennedy J, Long MJ, et al. Positron emission tomography/computerized \ntomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer. Journal of Oral & Maxillofa cial \nSurgery. 2007;65(12):2524 -35. \n80. Seitz O, Chambron -Pinho N, Middendorp M, Sader R, Mack M, Vogl TJ, et al. 18F -Fluorodeoxyglucose -PET/CT to evaluate \ntumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validati on \nwith surgical specime n. Neuroradiology. 2009;51(10):677 -86. \n81. Rao LP, Das SR, Mathews A, Naik BR, Chacko E, Pandey M. Mandibular invasion in oral squamous cell carcinoma: \ninvestigation by clinical examination and orthopantomogram. International Journal of Oral & Maxillofacia l Surgery. 2004;33(5):454 -7. \n82. Vidiri A, Ruscito P, Pichi B, Pellini R, Covello R, Sperduti I, et al. Oral cavity and base of the tongue tumors. Correlation  \nbetween clinical, MRI and pathological staging of primary tumor. Journal of Experimental and Clin ical Cancer Research. 2007;26 \n(4):575 -82. \n83. Vidiri A, Guerrisi A, Pellini R, Manciocco V, Covello R, Mattioni O, et al. Multi -detector row computed tomography (MDCT) \nand magnetic resonance imaging (MRI) in the evaluation of the mandibular invasion by squ amous cell carcinomas (SCC) of the oral \ncavity. Correlation with pathological data. J Exp Clin Cancer Res. 2010;29:73.  \n84. Babin E, Desmonts C, Hamon M, Benateau H, Hitier M. PET/CT for assessing mandibular invasion by intraoral squamous \ncell carcinomas. C lin Otolaryngol. 2008;33(1):47 -51. \n85. Baek C -H, Chung MK, Son Y -I, Choi JY, Kim H -J, Yim YJ, et al. Tumor volume assessment by 18F -FDG PET/CT in patients \nwith oral cavity cancer with dental artifacts on CT or MR images. J Nucl Med. 2008;49(9):1422 -8. \n86. Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss MO, et al. 18F -FET PET compared with 18F -FDG PET and CT in \npatients with head and neck cancer. J Nucl Med. 2006;47(2):256 -61. \n87. Dammann F, Horger M, Mueller -Berg M, Schlemmer H, Claussen CD, Ho ffman J, et al. Rational diagnosis of squamous cell \ncarcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET.[Erratum appears in AJR Am J Roentgen ol. \n2005 Jun;184(6):1968]. AJR Am J Roentgenol. 2005;184(4):1326 -31. \n88. Roh J -L, Yeo N -K, Kim JS, Lee JH, Cho K -J, Choi S -H, et al. Utility of 2 -[18F] fluoro -2-deoxy -D-glucose positron emission \ntomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck \nsquamous cell carcinoma . Oral Oncology. 2007;43(9):887 -93. \n89. Wiener E, Pautke C, Link TM, Neff A, Kolk A. Comparison of 16 -slice MSCT and MRI in the assessment of squamous cell \ncarcinoma of the oral cavity. Eur J Radiol. 2006;58(1):113 -8. \n90. Gu DH, Yoon DY, Park CH, Chang SK,  Lim KJ, Seo YL, et al. CT, MR, (18)F -FDG PET/CT, and their combined use for the \nassessment of mandibular invasion by squamous cell carcinomas of the oral cavity. Acta Radiol. 2010;51(10):1111 -9. \n91. van den Brekel MW, Castelijns JA, Stel HV, Golding RP, M eyer CJ, Snow GB. Modern imaging techniques and ultrasound -\nguided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolary ngol. \n1993;250(1):11 -7. Epub 1993/01/01.  \n92. Ng S -H, Yen T -C, Liao C -T, Chang JT -C, Chan S -C, Ko S -F, et al. 18F -FDG PET and CT/MRI in oral cavity squamous cell \ncarcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46(7):1136 -43. \n93. Ng S-H, Yen T -C, Chang JT -C, Chan S -C, Ko S -F, Wang H -M, et al. Prospective study of [18F]fluorodeoxyglucose positron \nemission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with \npalpably negative neck. Journal of Clinical Oncology. 2006;24(27):4371 -6. \n94. Sumi M, Kimura Y, Sumi T, Nakamura T. Diagnostic performance of MRI relative to CT for metastatic nodes of head and \nneck squamous cell carcinomas. J Magn Reson Imaging. 2007;26(6):1626 -33. \n95. Takes RP, Righi P, Meeuwis CA, Manni JJ, Knegt P, Marres HA , et al. The value of ultrasound with ultrasound -guided fine -\nneedle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative n eck. \nInt J Radiat Oncol Biol Phys. 1998;40(5):1027 -32. Epub 1998/04/16 . Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  27 \n96. Stokkel MP, ten Broek FW, Hordijk GJ, Koole R, van Rijk PP. Preoperative evaluation of patients with primary head and neck \ncancer using dual -head 18fluorodeoxyglucose positron emission tomography. Ann Surg. 2000;231(2):229 -34. Epub 2000/02/16.  \n97. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F -FDG PET with conventional imaging \nmodalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25(9):1255 -60. Epub 1998/09/02.  \n98. Balogova S, Peri e S, Kerrou K, Grahek D, Montravers F, Angelard B, et al. Prospective comparison of FDG and FET PET/CT in \npatients with head and neck squamous cell carcinoma. Mol Imaging Biol. 2008;10(6):364 -73. \n99. Jeong H -S, Baek C -H, Son Y -I, Ki Chung M, Kyung Lee D, Y oung Choi J, et al. Use of integrated 18F -FDG PET/CT to improve \nthe accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head & Neck. \n2007;29(3):203 -10. \n100. Kim SY, Roh JL, Kim JS, Ryu CH, Lee JH, Cho KJ, e t al. Utility of FDG PET in patients with squamous cell carcinomas of the \noral cavity. Eur J Surg Oncol. 2008;34(2):208 -15. \n101. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG -PET/CT imaging for preradiotherapy staging of \nhead -and-neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2005;61(1):129 -36. \n102. Gencoglu U, Guneren E, Gozu A, Ozsoy Z, Vural G. The coherence between fine needle aspiration cytology and \nhistopathology of palpable n eck nodes in lower lip carcinoma patients. European Journal of Plastic Surgery. 2003;26 (2):82 -4. \n103. Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, et al. Sentinel lymph node biopsy accurately stages the \nregional lymph nodes for T1 -T2 oral squamous cell carcinomas: results of a prospective multi -institutional trial. Journal of Clinical \nOncology. 2010;28(8):1395 -400. \n104. Cammilleri S, Lussato D, Guelfucci B, Lief F, Bellot V, Chrestian M, et al. Ability of lymphoscintigraphy to direct sentinel \nnode biopsy in the clinically NO check for patients with head and neck squamous cell carcinoma; a prospective study (prelimin ary \nresults). Bull Cancer. 2004;91(4):E1 -4. \n105. Burns P, Foster A, Walshe P, O'Dwyer T. Sentinel lymph node biopsy in nod e-negative squamous cell carcinoma of the oral \ncavity and oropharynx. Journal of Laryngology & Otology. 2009;123(4):439 -43. \n106. Hart RD, Nasser JG, Trites JR, Taylor SM, Bullock M, Barnes D. Sentinel lymph node biopsy in N0 squamous cell carcinoma \nof the oral cavity and oropharynx. Archives of Otolaryngology -- Head & Neck Surgery. 2005;131(1):34 -8. \n107. Hoft S, Maune S, Muhle C, Brenner W, Czech N, Kampen WU, et al. Sentinel lymph -node biopsy in head and neck cancer. \nBritish Journal of Cancer. 2004;91(1): 124-8. Epub 2004/06/10.  \n108. Keski -Santti H, Kontio R, Leivo I, Tornwall J, Matzke S, Makitie AA, et al. Sentinel lymph node biopsy as an alternative to \nwait and see policy in patients with small T1 oral cavity squamous cell carcinoma. Acta Otolaryngol (St ockh). 2008;128(1):98 -102. \n109. Schroeder U, Dietlein M, Wittekindt C, Ortmann M, Stuetzer H, Vent J, et al. Is there a need for positron emission \ntomography imaging to stage the N0 neck in T1 -T2 squamous cell carcinoma of the oral cavity or oropharynx? Annals of Otology, \nRhinology & Laryngology. 2008;117(11):854 -63. \n110. Nakamoto Y, Tamai K, Saga T, Higashi T, Hara T, Suga T, et al. Clinical value of image fusion from MR and PET in patients \nwith head and neck cancer. Mol Imaging Biol. 2009;11(1):46 -53. \n111. Jeong HS, Baek CH, Son YI, Cho DY, Man KC, Min JY, et al. Sentinel lymph node radiolocalization with 99mTc filtered tin \ncolloid in clinically node -negative squamous cell carcinomas of the oral cavity. Journal of Korean Medical Science. 2006;21 (5):865 -\n70. \n112. Pentenero M, Cistaro A, Brusa M, Ferraris MM, Pezzuto C, Carnino R, et al. Accuracy of 18F -FDG-PET/CT for staging of oral \nsquamous cell carcinoma. Head & Neck. 2008;30(11):1488 -96. \n113. Wensing BM, Vogel WV, Marres HAM, Merkx MAW, Postema EJ, Oye n WJG, et al. FDG-PET in the clinically negative neck in \noral squamous cell carcinoma.[Erratum appears in Laryngoscope. 2006 Jul;116(7 Pt 1):1302]. Laryngoscope. 2006;116(5):809 -13. \n114. Yamazaki Y, Saitoh M, Notani K -i, Tei K, Totsuka Y, Takinami S -i, et al. Assessment of cervical lymph node metastases \nusing FDG -PET in patients with head and neck cancer. Ann Nucl Med. 2008;22(3):177 -84. \n115. Piao Y, Bold B, Tayier A, Ishida R, Omura K, Okada N, et al. Evaluation of 18F -FDG PET/CT for diagnosing cervical no dal \nmetastases in patients with oral cavity or oropharynx carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. \n2009;108(6):933 -8. \n116. Kyzas PA, Evangelou E, Denaxa -Kyza D, Ioannidis JP. 18F -fluorodeoxyglucose positron emission tomography to evalua te \ncervical node metastases in patients with head and neck squamous cell carcinoma: a meta -analysis. Journal of the National Cancer \nInstitute. 2008;100(10):712 -20. Epub 2008/05/15.  \n117. Hohlweg -Majert B, Metzger MC, Voss PJ, Holzle F, Wolff K -D, Schulze D.  Preoperative cervical lymph node size evaluation in \npatients with malignant head/neck tumors: comparison between ultrasound and computer tomography. Journal of Cancer Research \n& Clinical Oncology. 2009;135(6):753 -9. \n118. Thomsen JB, Sorensen JA, Grupe P, Karstoft J, Krogdahl A. Staging N0 oral cancer: lymphoscintigraphy and conventional \nimaging. Acta Radiol. 2005;46(5):492 -6. \n119. To EWH, Tsang WM, Cheng J, Lai E, Pang P, Ahuja AT, et al. Is neck ultrasound necessary for early stage oral tongue \ncarcinoma w ith clinically N0 neck? Dentomaxillofac Radiol. 2003;32(3):156 -9. \n120. Alvarez Amezaga J, Barbier Herrero L, Pijoan del Barrio JI, Martin Rodriguez JC, Romo Simon L, Genolla Subirats J, et al. \nDiagnostic efficacy of sentinel node biopsy in oral squamous ce ll carcinoma. Cohort study and meta -analysis. Med Oral Patol Oral Cir \nBucal. 2007;12(3):E235 -43. \n121. Barzan L, Sulfaro S, Alberti F, Politi D, Pin M, Savignano MG, et al. An extended use of the sentinel node in head and neck \nsquamous cell carcinoma: resul ts of a prospective study of 100 patients. Acta Otorhinolaryngol Ital. 2004;24(3):145 -9. \n122. Burcia V, Costes V, Faillie JL, Gardiner Q, de Verbizier D, Cartier C, et al. Neck restaging with sentinel node biopsy in T1 -\nT2N0 oral and oropharyngeal cancer: W hy and how? Otolaryngology - Head & Neck Surgery. 2010;142(4):592 -7.e1.  \n123. Borgemeester MC, van den Brekel MWM, van Tinteren H, Smeele LE, Pameijer FA, van Velthuysen M -LF, et al. Ultrasound -\nguided aspiration cytology for the assessment of the clinically  N0 neck: factors influencing its accuracy. Head & Neck. \n2008;30(11):1505 -13. \n124. Brouwer J, de Bree R, Comans EFI, Castelijns JA, Hoekstra OS, Leemans CR. Positron emission tomography using \n[18F]fluorodeoxyglucose (FDG -PET) in the clinically negative nec k: is it likely to be superior? European Archives of Oto -Rhino -\nLaryngology. 2004;261(9):479 -83. \n125. Arunachalam PS, Putnam G, Jennings P, Messersmith R, Robson AK. Role of computerized tomography (CT) scan of the \nchest in patients with newly diagnosed hea d and neck cancers. Clin Otolaryngol Allied Sci. 2002;27(12383307):409 -11. \n126. Andrle J, Schartinger VH, Schwentner I, Deibl M, Sprinzl GM. Initial staging examinations for head and neck squamous cell \ncarcinoma: are they appropriate? J Laryngol Otol. 2009 ;123(8):885 -8. Epub 2009/04/18.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  28 \n127. Ghosh SK, Roland NJ, Kumar A, Tandon S, Lancaster JL, Jackson SR, et al. Detection of synchronous lung tumors in patients \npresenting with squamous cell carcinoma of the head and neck. Head & Neck. 2009;31(12):1563 -70. \n128. Loh KS, Brown DH, Baker JT, Gilbert RW, Gullane PJ, Irish JC. A rational approach to pulmonary screening in newly \ndiagnosed head and neck cancer. Head & Neck. 2005;27(11):990 -4. \n129. Bongers V, Hobbelink MG, van Rijk PP, Hordijk G -J. Cost -effectiveness  of dual -head 18F -fluorodeoxyglucose PET for the \ndetection of recurrent laryngeal cancer. Cancer Biother Radiopharm. 2002;17(12136522):303 -6. \n130. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglu cose for \nsuspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110(10983949):1493 -7. \n131. Haughey BH, Gates GA, Arfken CL, Harvey J. Meta -analysis of second malignant tumors in head and neck cancer: the case \nfor an endosco pic screening protocol. Ann Otol Rhinol Laryngol. 1992;101(2 Pt 1):105 -12. Epub 1992/02/01.  \n132. de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. \nLaryngoscope. 2000;110(3 Pt 1):397 -401. Epu b 2000/03/16.  \n133. Warner GC, Cox GJ. Evaluation of chest radiography versus chest computed tomography in screening for pulmonary \nmalignancy in advanced head and neck cancer. J Otolaryngol. 2003;32(12866595):107 -9. \n134. Keith DJW, Ong TK, Martin IC. The ro le of thoracic computed tomography in staging newly -diagnosed oral squamous cell \ncarcinoma. British Journal of Oral & Maxillofacial Surgery. 2006;44(3):198 -202. \n135. Bisase B, Kerawala C, Lee J. The role of computed tomography of the chest in the staging o f early squamous cell carcinoma \nof the tongue. British Journal of Oral & Maxillofacial Surgery. 2008;46(5):367 -9. \n136. Jungehulsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, et al. 2[F] -fluoro -2-deoxy -D-glucose positron \nemission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with \nhead and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000;123(3):294 -301. Epub 2000/08/30.  \n137. Johansen J, Eigtved A, Buchwald C, Th eilgaard SA, Hansen HS. Implication of 18F -fluoro -2-deoxy -D-glucose positron \nemission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. \nLaryngoscope. 2002;112(12439171):2009 -14. \n138. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, et al. Detection of unknown primary tumours and \ndistant metastases in patients with cervical metastases: value of FDG -PET versus conventional modalities. Eur J Nucl Med Mol \nImaging. 2002;29(8):1024 -30. Ep ub 2002/08/13.  \n139. Royal College of Pathologists. Standards and Datasets for Reporting Cancers: Datasets for histopathology reports on head \nand neck carcinomas and salivary neoplasms. 2nd Edition. London: The Royal College of Pathologists; 2005. [cited 11  August 2006]. \nAvailable from url: http://www.rcpath.org/resources/pdf/HeadNeckDatasetJun05.pdf . \n140. Coatesworth AP, MacLennan K. Squamous cell carcinoma of the upper aerodigestive  tract: the prevalence of microscopic \nextracapsular spread and soft tissue deposits in the clinically N0 neck. Head Neck. 2002;24(11891957):258 -61. \n141. Carinci F, Pelucchi S, Farina A, De Franciscis G, Calearo C. Extension as a prognostic factor in oropha ryngeal cancer: \nlargest mucosal dimension compared with number of (sub)sites involved. Br J Oral Maxillofac Surg. 1998;36(6):440 -5. \n142. Hirvikoski P, Kumpulainen E, Virtaniemi J, Pirinen R, Salmi L, Halonen P, et al. Enhanced apoptosis correlates with poo r \nsurvival in patients with laryngeal cancer but not with cell proliferation, bcl -2 or p53 expression. Eur J Cancer. \n1999;35(10448265):231 -7. \n143. Fortin A, Couture C, Doucet R, Albert M, Allard J, Tetu B. Does histologic grade have a role in the managemen t of head and \nneck cancers? J Clin Oncol. 2001;19(11689578):4107 -16. \n144. Yamazaki H, Inoue T, Teshima T, Tanaka E, Koizumi M, Kagawa K, et al. Tongue cancer treated with brachytherapy: is \nthickness of tongue cancer a prognostic factor for regional control ? Anticancer Res. 1998;18(2B):1261 -5. Epub 1998/06/06.  \n145. O'Brien CJ, Lauer CS, Fredricks S, Clifford AR, McNeil EB, Bagia JS, et al. Tumor thickness influences prognosis of T1 and T2  \noral cavity cancer --but what thickness? Head Neck. 2003;25(11):937 -45. Epub 2003/11/07.  \n146. Nishimaki T, Kanda T, Nakagawa S, Kosugi S -i, Tanabe T, Hatakeyama K. Outcomes and prognostic factors after surgical \nresection of hypopharyngeal and cervical esophageal carcinomas. Int Surg. 2002;87(1):38 -44. \n147. Barnes L, Eveson JW , Reichart P, Sidransky D, editors. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC \nPress; 2005. (WHO Classification of Tumours).  \n148. Ang KK, Berkey BA, Tu X, Zhang H -Z, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor exp ression \non survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(12499279):7350 -6. \n149. Spiro RH, Guillamondegui O, Paulino AF, Huvos AG. Pattern of invasion and margin assessment in patients with oral \ntongu e cancer. Head Neck. 1999;21(5):408 -13. \n150. Wong RJ, Keel SB, Glynn RJ, Varvares MA. Histological pattern of mandibular invasion by oral squamous cell carcinoma. \nLaryngoscope. 2000;110(1):65 -72. \n151. Weijers M, Snow GB, Bezemer PD, van der Wal JE, van der  Waal I. The clinical relevance of epithelial dysplasia in the \nsurgical margins of tongue and floor of mouth squamous cell carcinoma: an analysis of 37 patients. J Oral Pathol Med. \n2002;31(11896817):11 -5. \n152. Bailey JS, Blanchaert RH, Ord RA. Management o f oral squamous cell carcinoma treated with inadequate excisional biopsy. \nJ Oral Maxillofac Surg. 2001;59(11526566):1007 -10. \n153. McMahon J, O'Brien CJ, Pathak I, Hamill R, McNeil E, Hammersley N, et al. Influence of condition of surgical margins on \nlocal recurrence and disease -specific survival in oral and oropharyngeal cancer. Br J Oral Maxillofac Surg. 2003;41(4):224 -31. Epub \n2003/08/30.  \n154. Slootweg PJ, Hordijk GJ, Schade Y, van Es RJJ, Koole R. Treatment failure and margin status in head and neck canc er. A \ncritical view on the potential value of molecular pathology. Oral Oncol. 2002;38(12110346):500 -3. \n155. Ribeiro NFF, Godden DRP, Wilson GE, Butterworth DM, Woodwards RTM. Do frozen sections help achieve adequate surgical \nmargins in the resection of or al carcinoma? Int J Oral Maxillofac Surg. 2003;32(12729775):152 -8. \n156. DiNardo LJ, Lin J, Karageorge LS, Powers CN. Accuracy, utility, and cost of frozen section margins in head and neck cancer \nsurgery. Laryngoscope. 2000;110(10 Pt 1):1773 -6. Epub 2000/10 /19. \n157. Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, et al. Delayed regional metastases, distant \nmetastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope. \n2001;111(1140462 5):1079 -87. \n158. Ozdek A, Sarac S, Akyol MU, Unal OF, Sungur A. Histopathological predictors of occult lymph node metastases in \nsupraglottic squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2000;257(11052252):389 -92. Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  29 \n159. Parsons JT, Mendenhall WM, Str inger SP, Cassisi NJ, Million RR. An analysis of factors influencing the outcome of \npostoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys. 1997;39(1):137 -48. Epub \n1997/08/01.  \n160. Licitra L, Locati LD, Cavin a R, Garassino I, Mattavelli F, Pizzi N, et al. Primary chemotherapy followed by anterior \ncraniofacial resection and radiotherapy for paranasal cancer. Annals of oncology : official journal of the European Society f or Medical \nOncology / ESMO. 2003;14(3):36 7-72. Epub 2003/02/25.  \n161. Kovacs AF. Relevance of positive margins in case of adjuvant therapy of oral cancer. Int J Oral Maxillofac Surg. \n2004;33(5):447 -53. \n162. O'Brien CJ, Adams JR, McNeil EB, Taylor P, Laniewski P, Clifford A, et al. Influence of bon e invasion and extent of \nmandibular resection on local control of cancers of the oral cavity and oropharynx. Int J Oral Maxillofac Surg. 2003;32(5):49 2-7. \n163. Hicks WL, Loree TR, Garcia RI, Maamoun S, Marshall D, Orner JB, et al. Squamous cell carcinoma o f the floor of mouth: a \n20-year review. Head Neck. 1997;19(5):400 -5. \n164. Loree TR, Strong EW. Significance of positive margins in oral cavity squamous carcinoma. Am J Surg. 1990;160(4):410 -4. \n165. Brasilino de Carvalho M. Quantitative analysis of the exte nt of extracapsular invasion and its prognostic significance: a \nprospective study of 170 cases of carcinoma of the larynx and hypopharynx. Head Neck. 1998;20(1):16 -21. Epub 1998/02/17.  \n166. Tankere F, Camproux A, Barry B, Guedon C, Depondt J, Gehanno P. Pr ognostic value of lymph node involvement in oral \ncancers: a study of 137 cases. Laryngoscope. 2000;110(11129021):2061 -5. \n167. Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of \neven microscopic extracapsular spread. Oral Oncol. 2003;39(12509965):130 -7. \n168. Suoglu Y, Erdamar B, Katircioglu OS, Karatay MC, Sunay T. Extracapsular spread in ipsilateral neck and contralateral neck \nmetastases in laryngeal cancer. Ann Otol Rhinol Laryngol. 2002;111(5 Pt 1):447 -54. Epub 2002/05/23.  \n169. Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK, et al. Extent of extracapsular spread: a critical \nprognosticator in oral tongue cancer. Cancer. 2003;97(12627511):1464 -70. \n170. Esposito ED, Mott a S, Cassiano B, Motta G. Occult lymph node metastases in supraglottic cancers of the larynx. \nOtolaryngol Head Neck Surg. 2001;124(3):253 -7. Epub 2001/03/10.  \n171. Enepekides DJ, Sultanem K, Nguyen C, Shenouda G, Black MJ, Rochon L. Occult cervical metastas es: immunoperoxidase \nanalysis of the pathologically negative neck. Otolaryngol Head Neck Surg. 1999;120(5):713 -7. \n172. Byers RM, El -Naggar AK, Lee YY, Rao B, Fornage B, Terry NH, et al. Can we detect or predict the presence of occult nodal \nmetastases in pa tients with squamous carcinoma of the oral tongue? Head Neck. 1998;20(2):138 -44. Epub 1998/03/04.  \n173. Ferlito A, Partridge M, Brennan J, Hamakawa H. Lymph node micrometastases in head and neck cancer: a review. Acta \nOtolaryngol. 2001;121(6):660 -5. Epub 20 01/10/27.  \n174. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the \noropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92(4):805 -13. Epub 2001/09/11.  \n175. Buchwald C, Lindeberg H, Pedersen BL, Franzmann MB. Human papilloma virus and p53 expression in carcinomas \nassociated with sinonasal papillomas: a Danish Epidemiological study 1980 -1998. Laryngoscope. 2001;111(6):1104 -10. Epub \n2001/06/19.  \n176. Friesland S, Mellin H , Munck -Wikland E, Nilsson A, Lindholm J, Dalianis T, et al. Human papilloma virus (HPV) and p53 \nimmunostaining in advanced tonsillar carcinoma --relation to radiotherapy response and survival. Anticancer Res. 2001;21(1B):529 -\n34. Epub 2001/04/13.  \n177. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human \npapillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709 -20. Epub \n2000/05/04.  \n178. Takes R P, Baatenburg De Jong RJ, Alles MJ, Meeuwis CA, Marres HA, Knegt PP, et al. Markers for nodal metastasis in head \nand neck squamous cell cancer. Arch Otolaryngol Head Neck Surg. 2002;128(5):512 -8. Epub 2002/05/11.  \n179. Helliwell TR. Molecular markers of met astasis in squamous carcinomas. The Journal of pathology. 2001;194(3):289 -93. \nEpub 2001/07/06.  \n180. Newell R, Ziegler L, Stafford N, Lewin RJ. The information needs of head and neck cancer patients prior to surgery. Annals \nof the Royal College of Surgeons of England. 2004;86(6):407 -10. Epub 2004/11/06.  \n181. Epstein JB, Lunn R, Le N, Stevenson -Moore P. Periodontal attachment loss in patients after head and neck radiation \ntherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86(6):673 -7. Epub 1998/1 2/30.  \n182. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94 -01 randomized trial \ncomparing radiotherapy with concomitant radiochemotherapy for advanced -stage oropharynx carcinoma: comparison of \nLENT/SO MA, RTOG/EORTC, and NCI -CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003;55(1):93 -8. Epub 2002/12/31.  \n183. dos Santos CR, Goncalves Filho J, Magrin J, Johnson LF, Ferlito A, Kowalski LP. Involvement of level I neck lymph nodes in \nadvanced squamous c arcinoma of the larynx. Ann Otol Rhinol Laryngol. 2001;110(10):982 -4. Epub 2001/10/20.  \n184. Johansen LV, Grau C, Overgaard J. Hypopharyngeal squamous cell carcinoma --treatment results in 138 consecutively \nadmitted patients. Acta Oncol. 2000;39(4):529 -36. E pub 2000/10/21.  \n185. Rodgers LW, Jr., Stringer SP, Mendenhall WM, Parsons JT, Cassisi NJ, Million RR. Management of squamous cell carcinoma \nof the floor of mouth. Head Neck. 1993;15(1):16 -9. Epub 1993/01/01.  \n186. Levendag PC, Nowak PJ, van der Sangen MJ, Jansen PP, Eijkenboom WM, Planting AS, et al. Local tumor control in radiation \ntherapy of cancers in the head and neck. Am J Clin Oncol. 1996;19(5):469 -77. \n187. Crampette L, Garrel R, Gardiner Q, Maurice N, Mondain M, Makeieff M, et al. Modified subtotal l aryngectomy with \ncricohyoidoepiglottopexy --long term results in 81 patients. Head Neck. 1999;21(2):95 -103. Epub 1999/03/26.  \n188. Giovanni A, Guelfucci B, Gras R, Yu P, Zanaret M. Partial frontolateral laryngectomy with epiglottic reconstruction for \nmanagem ent of early -stage glottic carcinoma. Laryngoscope. 2001;111(4 Pt 1):663 -8. Epub 2001/05/19.  \n189. Luukkaa M, Aitasalo K, Pulkkinen J, Lindholm P, Valavaara R, Grenman R. Neodymium YAG contact laser in the treatment of \ncancer of the mobile tongue. Acta Otol aryngol. 2002;122(3):318 -22. Epub 2002/05/28.  \n190. Edwards DM, Johnson NW. Treatment of upper aerodigestive tract cancers in England and its effect on survival. Br J Cancer. \n1999;81(2):323 -9. Epub 1999/09/25.  \n191. Bahadur S, Thakar A, Mohanti BK, Lal P. Re sults of radiotherapy with, or without, salvage surgery versus combined surgery \nand radiotherapy in advanced carcinoma of the hypopharynx. J Laryngol Otol. 2002;116(1):29 -32. Epub 2002/02/28.  \n192. Leon X, Quer M, Orus C, Moran J, Recher K. Results of an or gan preservation protocol with induction chemotherapy and \nradiotherapy in patients with locally advanced pyriform sinus carcinoma. Eur Arch Otorhinolaryngol. 2002;259(1):32 -6. Epub \n2002/04/17.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  30 \n193. Barzan L, Talamini R, Politi D, Minatel E, Gobitti C, Fran chin G. Squamous cell carcinoma of the hypopharynx treated with \nsurgery and radiotherapy. J Laryngol Otol. 2002;116(1):24 -8. Epub 2002/02/28.  \n194. MacKenzie RG, Franssen E, Balogh JM, Gilbert RW, Birt D, Davidson J. Comparing treatment outcomes of radiothe rapy and \nsurgery in locally advanced carcinoma of the larynx: a comparison limited to patients eligible for surgery. Int J Radiat Onco l Biol \nPhys. 2000;47(1):65 -71. Epub 2000/04/12.  \n195. Porter MJ, McIvor NP, Morton RP, Hindley AC. Audit in the management of T3 fixed -cord laryngeal cancer. Am J \nOtolaryngol. 1998;19(6):360 -4. Epub 1998/12/05.  \n196. Staton J, Robbins KT, Newman L, Samant S, Sebelik M, Vieira F. Factors predictive of poor functional outcome after \nchemoradiation for advanced laryngeal cancer. Otolaryngol Head Neck Surg. 2002;127(1):43 -7. Epub 2002/08/06.  \n197. Terrell JE, Fisher SG, Wolf GT. Long -term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal \nCancer Study Group. Arch Otolaryngol Head Neck Surg. 1998;124( 9):964 -71. Epub 1998/09/17.  \n198. Bergqvist M, Brodin O, Pouzon A, Linder A, Hesselius P, Blomquist E. Radiation treatment of T1 -T4 squamous cell \ncarcinoma of the larynx: a retrospective analysis and long -term follow -up of 135 patients. Anticancer Res. 2002 ;22(2B):1239 -42. \nEpub 2002/08/10.  \n199. Paisley S, Warde PR, O'Sullivan B, Waldron J, Gullane PJ, Payne D, et al. Results of radiotherapy for primary subglottic \nsquamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(5):1245 -50. Epub 2002/04/17.  \n200. Orus C, Leon X, Vega M, Quer M. Initial treatment of the early stages (I, II) of supraglottic squamous cell carcinoma: partia l \nlaryngectomy versus radiotherapy. Eur Arch Otorhinolaryngol. 2000;257(9):512 -6. Epub 2000/12/29.  \n201. Medini E, Medini I, Lee CK , Gapany M, Levitt SH. Curative radiotherapy for stage II -III squamous cell carcinoma of the \nglottic larynx. Am J Clin Oncol. 1998;21(3):302 -5. Epub 1998/06/17.  \n202. Lavertu P, Bonafede JP, Adelstein DJ, Saxton JP, Strome M, Wanamaker JR, et al. Comparison  of surgical complications after \norgan -preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg. \n1998;124(4):401 -6. Epub 1998/04/29.  \n203. Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Ca ssisi NJ. Radiation therapy for squamous cell carcinoma of the \ntonsillar region: a preferred alternative to surgery? J Clin Oncol. 2000;18(11):2219 -25. Epub 2000/06/01.  \n204. Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Moore -Higgs GJ, Cassisi NJ. Is radiation therapy a preferred \nalternative to surgery for squamous cell carcinoma of the base of tongue? J Clin Oncol. 2000;18(1):35 -42. Epub 2000/01/07.  \n205. Tschudi D, Stoeckli S, Schmid S. Quality of life after different treatment modalities for carcinom a of the oropharynx. \nLaryngoscope. 2003;113(11):1949 -54. Epub 2003/11/07.  \n206. Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, et al. Induction chemotherapy with paclitaxel and \ncisplatin and CT -based 3D radiotherapy in patients with a dvanced laryngeal and hypopharyngeal carcinomas --a possibility for organ \npreservation. Radiother Oncol. 2003;68(2):163 -70. Epub 2003/09/16.  \n207. Sessions DG, Spector GJ, Lenox J, Parriott S, Haughey B, Chao C, et al. Analysis of treatment results for floor -of-mouth \ncancer. Laryngoscope. 2000;110(10):1764 -72. \n208. Sutton DN, Brown JS, Rogers SN, Vaughan ED, Woolgar JA. The prognostic implications of the surgical margin in oral \nsquamous cell carcinoma. Int J Oral Maxillofac Surg. 2003;32(1):30 -4. \n209. Brown J S, Kalavrezos N, D'Souza J, Lowe D, Magennis P, Woolgar JA. Factors that influence the method of mandibular \nresection in the management of oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2002;40(4):275 -84. \n210. Wolff D, Hassfeld S, Hofele C. Influ ence of marginal and segmental mandibular resection on the survival rate in patients \nwith squamous cell carcinoma of the inferior parts of the oral cavity. J Craniomaxillofac Surg. 2004;32(5):318 -23. \n211. Munoz Guerra MF, Naval Gias L, Campo FR, Perez JS. Marginal and segmental mandibulectomy in patients with oral cancer: \na statistical analysis of 106 cases. J Oral Maxillofac Surg. 2003;61(11):1289 -96. \n212. Muscatello L, Lenzi R, Pellini R, Giudice M, Spriano G. Marginal mandibulectomy in oral cancer surger y: A 13 -year \nexperience. European Archives of Oto -Rhino -Laryngology. 2010;267 (5):759 -64. \n213. Abler A, Roser M, Weingart D. [On the indications for and morbidity of segmental resection of the mandible for squamous \ncell carcinoma in the lower oral cavity].  Mund Kiefer Gesichtschir. 2005;9(3):137 -42. Zur Indikation und Morbiditat der \nKontinuitatsresektion des Unterkiefers beim Plattenepithelkarzinom der unteren Mundhohlenetage.  \n214. Namaki S, Matsumoto M, Ohba H, Tanaka H, Koshikawa N, Shinohara M. Masticato ry efficiency before and after surgery in \noral cancer patients: comparative study of glossectomy, marginal mandibulectomy and segmental mandibulectomy. J Oral Sci. \n2004;46(2):113 -7. \n215. Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, et al. Surgery and adj uvant radiotherapy vs concurrent chemoradiotherapy \nin stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005;93(3):279 -86. Epub \n2005/07/14.  \n216. Lefebvre JL, Coche -Dequeant B, Buisset E, Mirabel X, Van JT,  Prevost B. Management of early oral cavity cancer. Experience \nof Centre Oscar Lambret. Eur J Cancer B Oral Oncol. 1994;30(3):216 -20. Epub 1994/05/01.  \n217. Panje WR, Smith B, McCabe BF. Epidermoid carcinoma of the floor of the mouth: surgical therapy vs co mbined therapy vs \nradiation therapy. Otolaryngol Head Neck Surg. 1980;88(6):714 -20. \n218. Iyer SG, Pradhan SA, Pai PS, Patil S. Surgical treatment outcomes of localized squamous carcinoma of buccal mucosa. Head \nNeck. 2004;26(10):897 -902. \n219. Turner SL, Sle vin NJ, Gupta NK, Swindell R. Radical external beam radiotherapy for 333 squamous carcinomas of the oral \ncavity --evaluation of late morbidity and a watch policy for the clinically negative neck. Radiother Oncol. 1996;41(1):21 -9. Epub \n1996/10/01.  \n220. Glanz mann C, Gratz KW. Radionecrosis of the mandibula: a retrospective analysis of the incidence and risk factors. \nRadiother Oncol. 1995;36(2):94 -9100.  \n221. Zelefsky MJ, Harrison LB, Fass DE, Armstrong JG, Shah JP, Strong EW. Postoperative radiation therapy for  squamous cell \ncarcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins. Int J Radiat Onco l Biol \nPhys. 1993;25(1):17 -21. \n222. Rogers SN, Devine J, Lowe D, Shokar P, Brown JS, Vaugman ED. Longitudinal health -related quality of life after mandibular \nresection for oral cancer: a comparison between rim and segment. Head & Neck. 2004;26(1):54 -62. \n223. Spiro RH, Morgan GJ, Strong EW, Shah JP. Supraomohyoid neck dissection. Am J Surg. 1996;172(8988669):650 -3. \n224. Nieuwenhuis EJC, Castelijns JA, Pijpers R, van den Brekel MWM, Brakenhoff RH, van der Waal I, et al. Wait-and-see policy for \nthe N0 neck in early -stage oral and oropharyngeal squamous cell carcinoma using ultrasonography -guided cytology: is there a role \nfor identification of the sentinel node? Head Neck. 2002;24(11891961):282 -9. Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  31 \n225. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral \ncavity. Cancer. 1990;66(1):109 -13. \n226. Spiro JD, Spiro RH,  Shah JP, Sessions RB, Strong EW. Critical assessment of supraomohyoid neck dissection. Am J Surg. \n1988;156(4):286 -9. \n227. Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified neck dissection. Head Neck Surg. 1988;10(3):160 -7. \n228. Smith GI, O 'Brien CJ, Clark J, Shannon KF, Clifford AR, McNeil EB, et al. Management of the neck in patients with T1 and T2 \ncancer in the mouth. Br J Oral Maxillofac Surg. 2004;42(6):494 -500. Epub 2004/11/17.  \n229. Crean S -J, Hoffman A, Potts J, Fardy MJ. Reduction of  occult metastatic disease by extension of the supraomohyoid neck \ndissection to include level IV. Head Neck. 2003;25(12953312):758 -62. \n230. Hao S -P, Tsang NM. The role of supraomohyoid neck dissection in patients of oral cavity carcinoma(small star, filled ). Oral \nOncol. 2002;38(11978555):309 -12. \n231. O'Brien CJ, Traynor SJ, McNeil E, McMahon JD, Chaplin JM. The use of clinical criteria alone in the management of the \nclinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx. Arch Otolaryngol Head \nNeck Surg. 2000;126(3):360 -5. Epub 2000/03/18.  \n232. Henick DH, Silver CE, Heller KS, Shaha AR, El GH, Wolk DP. Supraomohyoid neck dissection as a staging procedure for \nsquamous cell carcinomas of the oral cavity and oropha rynx. Head Neck. 1995;17(2):119 -23. \n233. Cole I, Hughes L. The relationship of cervical lymph node metastases to primary sites of carcinoma of the upper \naerodigestive tract: a pathological study. Aust N Z J Surg. 1997;67(12):860 -5. \n234. McGuirt WF, Johnson  JT, Myers EN, Rothfield R, Wagner R. Floor of mouth carcinoma. The management of the clinically \nnegative neck. Arch Otolaryngol Head Neck Surg. 1995;121(7873143):278 -82. \n235. Kligerman J, Lima RA, Soares JR, Prado L, Dias FL, Freitas EQ, et al. Supraomohy oid neck dissection in the treatment of \nT1/T2 squamous cell carcinoma of oral cavity. Am J Surg. 1994;168(7977957):391 -4. \n236. Johnson JT. Carcinoma of the larynx: selective approach to the management of cervical lymphatics. Ear Nose Throat J. \n1994;73(5):3 03-5. Epub 1994/05/01.  \n237. Manni JJ, van den Hoogen FJ. Supraomohyoid neck dissection with frozen section biopsy as a staging procedure in the \nclinically node -negative neck in carcinoma of the oral cavity. Am J Surg. 1991;162(4):373 -6. \n238. Leon X, Quer M , Orus C, Sancho FJ, Bague S, Burgues J. Selective dissection of levels II -III with intraoperative control of the \nupper and middle jugular nodes: a therapeutic option for the N0 neck. Head Neck. 2001;23(6):441 -6. \n239. Byers RM. Modified neck dissection. A study of 967 cases from 1970 to 1980. Am J Surg. 1985;150(4):414 -21. Epub \n1985/10/01.  \n240. Bocca E, Pignataro O, Oldini C, Cappa C. Functional neck dissection: an evaluation and review of 843 cases. Laryngoscope. \n1984;94(7):942 -5. \n241. Molinari R, Cantu G,  Chiesa F, Grandi C. Retrospective comparison of conservative and radical neck dissection in laryngeal \ncancer. Ann Otol Rhinol Laryngol. 1980;89(6 Pt 1):578 -81. Epub 1980/11/01.  \n242. Spiro RH, Gallo O, Shah JP. Selective jugular node dissection in patients  with squamous carcinoma of the larynx or \npharynx. Am J Surg. 1993;166(4):399 -402. \n243. Bier J. Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent \nResults Cancer Res. 1994;134:57 -62. \n244. Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the \nmanagement of oral squamous carcinoma. Brazilian Head and Neck Cancer Study Group. Am J Surg. 1998;176(5):422 -7. Epub \n1999/01/05.  \n245. Fakih AR, R ao RS, Borges AM, Patel AR. Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. \nAm J Surg. 1989;158(4):309 -13. \n246. van den Brekel MW, Castelijns JA, Snow GB. Diagnostic evaluation of the neck. Otolaryngol Clin North Am. 1998 ;31(4):601 -\n20. Epub 1998/08/01.  \n247. Ho CM, Lam KH, Wei WI, Lau WF. Treatment of neck nodes in oral cancer. Surg Oncol. 1992;1(1341238):73 -8. \n248. Lydiatt DD, Robbins KT, Byers RM, Wolf PF. Treatment of stage I and II oral tongue cancer. Head Neck. 1993;15 (4):308 -12. \n249. Grandi C, Mingardo M, Guzzo M, Licitra L, Podrecca S, Molinari R. Salvage surgery of cervical recurrences after neck \ndissection or radiotherapy. Head Neck. 1993;15(4):292 -5. \n250. Vandenbrouck C, Sancho -Garnier H, Chassagne D, Saravane D, C achin Y, Micheau C. Elective versus therapeutic radical \nneck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. Cancer. 1980;46(2):386 -90. \n251. Dias FL, Kligerman J, Matos de Sa G, Arcuri RA, Freitas EQ, Farias T , et al. Elective neck dissection versus observation in \nstage I squamous cell carcinomas of the tongue and floor of the mouth. Otolaryngol Head Neck Surg. 2001;125(1):23 -9. \n252. Wolfensberger M, Zbaeren P, Dulguerov P, Muller W, Arnoux A, Schmid S. Surgica l treatment of early oral carcinoma -results \nof a prospective controlled multicenter study. Head Neck. 2001;23(7):525 -30. \n253. D'Cruz AK, Siddachari RC, Walvekar RR, Pantvaidya GH, Chaukar DA, Deshpande MS, et al. Elective neck dissection for the \nmanagement  of the N0 neck in early cancer of the oral tongue: need for a randomized controlled trial. Head & Neck. 2009;31(5):618 -\n24. \n254. Huang S -F, Kang C -J, Lin C -Y, Fan K -H, Yen T -C, Wang H -M, et al. Neck treatment of patients with early stage oral tongue \ncancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008;112(5):1066 -75. \n255. Akhtar S, Ikram M, Ghaffar S. Neck involvement in early carcinoma of tongue. Is elective neck dissection warranted? JPMA J \nPak Med Assoc. 2007;57(6):305 -7. \n256. Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck dissection classification update: revisions \nproposed by the American Head and Neck Society and the American Academy of Otolaryngology -Head and Neck S urgery. Arch \nOtolaryngol Head Neck Surg. 2002;128(12117328):751 -8. \n257. Piedbois P, Mazeron JJ, Haddad E, Coste A, Martin M, Levy C, et al. Stage I -II squamous cell carcinoma of the oral cavity \ntreated by iridium -192: is elective neck dissection indicated?  Radiother Oncol. 1991;21(2):100 -6. \n258. Yuen AP, Wei WI, Lam LK, Ho WK, Kwong D. Results of surgical salvage of locoregional recurrence of carcinoma of the \ntongue after radiotherapy failure. Ann Otol Rhinol Laryngol. 1997;106(9):779 -82. \n259. Weiss MH, Har rison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch \nOtolaryngol Head Neck Surg. 1994;120(8018319):699 -702. \n260. Iype EM, Sebastian P, Mathew A, Balagopal PG, Varghese BT, Thomas S. The role of selecti ve neck dissection (I -III) in the \ntreatment of node negative (N0) neck in oral cancer. Oral Oncology. 2008;44(12):1134 -8. Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  32 \n261. Yuen AP -W, Ho CM, Chow TL, Tang LC, Cheung WY, Ng RW -M, et al. Prospective randomized study of selective neck \ndissection versus o bservation for N0 neck of early tongue carcinoma. Head & Neck. 2009;31(6):765 -72. \n262. Jin WL, Ye WM, Zheng JW, Zhou L, Zhu HG, Zhang ZY, et al. Occult cervical lymph node metastases in 100 consecutive \npatients with cN0 tongue cancer. Chinese Medical Journ al. 2008;121 (19):1871 -4. \n263. Byers RM, Weber RS, Andrews T, McGill D, Kare R, Wolf P. Frequency and therapeutic implications of \"skip metastases\" in \nthe neck from squamous carcinoma of the oral tongue. Head Neck. 1997;19(1):14 -9. Epub 1997/01/01.  \n264. Corlette TH, Cole IE, Albsoul N, Ayyash M. Neck dissection of level IIb: is it really necessary? Laryngoscope. \n2005;115(9):1624 -6. \n265. Elsheikh MN, Mahfouz ME, Elsheikh E. Level IIb lymph nodes metastasis in elective supraomohyoid neck dissection for oral  \ncavity squamous cell carcinoma: a molecular -based study. Laryngoscope. 2005;115(9):1636 -40. \n266. Lim YC, Song MH, Kim SC, Kim KM, Choi EC. Preserving level IIb lymph nodes in elective supraomohyoid neck dissection \nfor oral cavity squamous cell carcinoma. Archives of Otolaryngology -- Head & Neck Surgery. 2004;130(9):1088 -91. \n267. Santoro R, Franchi A, Gallo O, Burali G, de' Campora E. Nodal metastases at level IIb during neck dissection for head and \nneck cancer: clinical and pathologic evaluation. Head & N eck. 2008;30(11):1483 -7. \n268. Kowalski LP, Bagietto R, Lara JR, Santos RL, Tagawa EK, Santos IR. Factors influencing contralateral lymph node metastasis \nfrom oral carcinoma. Head Neck. 1999;21(2):104 -10. \n269. De Zinis LOR, Bolzoni A, Piazza C, Nicolai P. P revalence and localization of nodal metastases in squamous cell carcinoma \nof the oral cavity: role and extension of neck dissection. European Archives of Oto -Rhino -Laryngology. 2006;263(12):1131 -5. \n270. Yu S, Li J, Li Z, Zhang W, Zhao J. Efficacy of suprao mohyoid neck dissection in patients with oral squamous cell carcinoma \nand negative neck. American Journal of Surgery. 2006;191(1):94 -9. \n271. Liaw G -A, Yen C -Y, Chiang W -F, Lee C -H, Yang C, Chiou C -T, et al. Outcome of treatment with total main tumor resect ion \nand supraomohyoid neck dissection in oral squamous cell carcinoma. J Formos Med Assoc. 2006;105(12):971 -7. \n272. Inoue H, Nibu K -I, Saito M, Otsuki N, Ishida H, Onitsuka T, et al. Quality of life after neck dissection. Archives of \nOtolaryngology -- Head  & Neck Surgery. 2006;132(6):662 -6. \n273. Laverick S, Lowe D, Brown JS, Vaughan ED, Rogers SN. The Impact of Neck Dissection on Health -Related Quality of Life. \nArchives of Otolaryngology - Head and Neck Surgery. 2004;130 (2):149 -54. \n274. Jesse RH, Ballantyn e AJ, Larson D. Radical or modified neck dissection: a therapeutic dilemma. Am J Surg. \n1978;136(707734):516 -9. \n275. Lingeman RE, Helmus C, Stephens R, Ulm J. Neck dissection: radical or conservative. Ann Otol Rhinol Laryngol. 1977;86(6 \nPt 1):737 -44. Epub 1 977/11/01.  \n276. Brandenburg JH, Lee CY. The eleventh nerve in radical neck surgery. Laryngoscope. 1981;91(11):1851 -9. \n277. Andersen PE, Shah JP, Cambronero E, Spiro RH. The role of comprehensive neck dissection with preservation of the spinal \naccessory ner ve in the clinically positive neck. Am J Surg. 1994;168(7977984):499 -502. \n278. Bocca E, Pignataro O. A conservation technique in radical neck dissection. Ann Otol Rhinol Laryngol. 1967;76(5):975 -87. \n279. Chu W, Strawitz JG. Results in suprahyoid, modified radical, and standard radical neck dissections for metastatic \nsquamous cell carcinoma: recurrence and survival. Am J Surg. 1978;136(707733):512 -5. \n280. Kohler HF, Cunha IWd, Kowalski LP. Impact of modified radical neck dissections on the number of retrieve d nodes, \nrecurrence and survival. Rev Bras Otorrinolaringol (Engl Ed). 2010;76(3):374 -7. \n281. Patel RS, Clark JR, Gao K, O'Brien CJ. Effectiveness of selective neck dissection in the treatment of the clinically positive  \nneck. Head & Neck. 2008;30(9):1231 -6. \n282. Rapoport A, Ortellado DK, Amar A, Lehn CN, Dedivitis RA, Perez RS, et al. Radical versus supraomohyoid neck dissection in \nthe treatment of squamous cell carcinoma of the inferior level of the mouth. Rev Bras Otorrinolaringol (Engl Ed). 2007;73(5): 641-6. \n283. Chepeha DB, Hoff PT, Taylor RJ, Bradford CR, Teknos TN, Esclamado RM. Selective neck dissection for the treatment of \nneck metastasis from squamous cell carcinoma of the head and neck. Laryngoscope. 2002;112(12148849):434 -8. \n284. Andersen PE, Warren F, Spiro J, Burningham A, Wong R, Wax MK, et al. Results of selective neck dissection in management \nof the node -positive neck. Arch Otolaryngol Head Neck Surg. 2002;128(12365890):1180 -4. \n285. Shepard PM, Olson J, Harari PM, Leverson G, Hartig GK. Th erapeutic selective neck dissection outcomes. Otolaryngology - \nHead & Neck Surgery. 2010;142(5):741 -6. \n286. Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA, et al. Necessity for adjuvant neck dissection in setting \nof concurrent chemoradia tion for advanced head -and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58(15050318):1418 -23. \n287. Frank DK, Hu KS, Culliney BE, Persky MS, Nussbaum M, Schantz SP, et al. Planned neck dissection after concomitant \nradiochemotherapy for advanced head and neck cancer. Laryngoscope. 2005;115(15933512):1015 -20. \n288. Wang SJ, Wang MB, Yip H, Calcaterra TC. Combined radiotherapy with planned neck dissection for small head and neck \ncancers with advanced cervical metastases. Laryngoscope. 2000;110(11081586):1794 -7. \n289. Ritoe SC, Krabbe PF, Jansen MM, Festen J, Joosten FB, Kaanders JH, et al. Screening for second primary lung cancer after \ntreatment of laryngeal cancer. Laryngoscope. 2002;112(11):2002 -8. Epub 2002/11/20.  \n290. Koo BS, Lim YC, Lee JS, Choi EC. Manage ment of contralateral N0 neck in oral cavity squamous cell carcinoma. Head & \nNeck. 2006;28(10):896 -901. \n291. Pathak KA, Das AK, Agarwal R, Talole S, Deshpande MS, Chaturvedi P, et al. Selective neck dissection (I -III) for node \nnegative and node positive ne cks. Oral Oncology. 2006;42 (8):837 -41. \n292. Vikram B, Strong EW, Shah JP, Spiro R. Failure in the neck following multimodality treatment for advanced head and neck \ncancer. Head Neck Surg. 1984;6(3):724 -9. Epub 1984/01/01.  \n293. Bernier J, Domenge C, Ozsahi n M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without \nconcomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945 -52. Epub 2004/05/07.  \n294. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and \nchemotherapy for high -risk squamous -cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937 -44. Epub 2004/05/07.  \n295. Argiris A, Stenson KM, Brockstein BE, Mitt al BB, Pelzer H, Kies MS, et al. Neck dissection in the combined -modality therapy \nof patients with locoregionally advanced head and neck cancer. Head Neck. 2004;26(15122662):447 -55. \n296. Clayman GL, Johnson CJ, Morrison W, Ginsberg L, Lippman SM. The role of neck dissection after chemoradiotherapy for \noropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg. 2001;127(11177029):135 -9. \n297. Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after  irradiation alone for head \nand neck squamous cell carcinoma with clinically positive neck nodes. Head Neck. 1999;21(7):591 -4. \n298. Byers RM, Clayman GL, Guillamondequi OM, Peters LJ, Goepfert H. Resection of advanced cervical metastasis prior to \ndefinitiv e radiotherapy for primary squamous carcinomas of the upper aerodigestive tract. Head Neck. 1992;14(2):133 -8. Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  33 \n299. Reddy AN, Eisele DW, Forastiere AA, Lee DJ, Westra WH, Califano JA. Neck dissection followed by radiotherapy or \nchemoradiotherapy for small p rimary oropharynx carcinoma with cervical metastasis. Laryngoscope. 2005;115(7):1196 -200. Epub \n2005/07/05.  \n300. Villaret DB, Futran NA. The indications and outcomes in the use of osteocutaneous radial forearm free flap. Head Neck. \n2003;25(6):475 -81. Epub 2 003/06/05.  \n301. Suh JD, Sercarz JA, Abemayor E, Calcaterra TC, Rawnsley JD, Alam D, et al. Analysis of outcome and complications in 400 \ncases of microvascular head and neck reconstruction. Arch Otolaryngol Head Neck Surg. 2004;130(8):962 -6. Epub 2004/08/18 . \n302. Castelli ML, Pecorari G, Succo G, Bena A, Andreis M, Sartoris A. Pectoralis major myocutaneous flap: analysis of \ncomplications in difficult patients. Eur Arch Otorhinolaryngol. 2001;258(10):542 -5. Epub 2002/02/07.  \n303. Chiarini L, De Santis G, Bedog ni A, Nocini PF. Lining the mouth floor with prelaminated fascio -mucosal free flaps: clinical \nexperience. Microsurgery. 2002;22(5):177 -86. Epub 2002/09/05.  \n304. Azizzadeh B, Yafai S, Rawnsley JD, Abemayor E, Sercarz JA, Calcaterra TC, et al. Radial forearm  free flap \npharyngoesophageal reconstruction. Laryngoscope. 2001;111(5):807 -10. Epub 2001/05/19.  \n305. Jol JK, Quak JJ, de Bree R, Leemans CR. Larynx preservation surgery for advanced posterior pharyngeal wall carcinoma with \nfree flap reconstruction: a crit ical appraisal. Oral Oncol. 2003;39(6):552 -8. Epub 2003/06/12.  \n306. Disa JJ, Pusic AL, Hidalgo DA, Cordeiro PG. Microvascular reconstruction of the hypopharynx: defect classification, \ntreatment algorithm, and functional outcome based on 165 consecutive cas es. Plastic and reconstructive surgery. 2003;111(2):652 -\n60; discussion 61 -3. Epub 2003/02/01.  \n307. Genden EM, Kaufman MR, Katz B, Vine A, Urken ML. Tubed gastro -omental free flap for pharyngoesophageal \nreconstruction. Arch Otolaryngol Head Neck Surg. 2001; 127(7):847 -53. Epub 2001/08/04.  \n308. Hayden RE, Deschler DG. Lateral thigh free flap for head and neck reconstruction. Laryngoscope. 1999;109(9):1490 -4. \nEpub 1999/09/28.  \n309. Makitie AA, Beasley NJ, Neligan PC, Lipa J, Gullane PJ, Gilbert RW. Head and neck  reconstruction with anterolateral thigh \nflap. Otolaryngol Head Neck Surg. 2003;129(5):547 -55. Epub 2003/11/05.  \n310. Julieron M, Germain MA, Schwaab G, Marandas P, Bourgain JL, Wibault P, et al. Reconstruction with free jejunal autograft \nafter circumferent ial pharyngolaryngectomy: eighty -three cases. Ann Otol Rhinol Laryngol. 1998;107(7):581 -7. Epub 1998/07/31.  \n311. Duncan W, MacDougall RH, Kerr GR, Downing D. Adverse effect of treatment gaps in the outcome of radiotherapy for \nlaryngeal cancer. Radiother On col. 1996;41(3):203 -7. Epub 1996/12/01.  \n312. Robertson C, Robertson AG, Hendry JH, Roberts SA, Slevin NJ, Duncan WB, et al. Similar decreases in local tumor control \nare calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J \nRadiat Oncol Biol Phys. 1998;40(2):319 -29. Epub 1998/02/11.  \n313. Board of the Faculty of Clinical Oncology. Guidelines for the Management of the Unscheduled Interruption or Prolongation \nof a Radical Course of Radiotherapy. 2nd Edition. London: The Royal College of Radiologists; 2002. [cited 11 August 2006]. Available \nfrom url: http://www.rcr.ac.uk/docs/oncology/pdf/gaps.pdf . \n314. Cox JD, Stetz J, Paj ak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization \nfor Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341 -6. Epub 1995/03/30.  \n315. Rubin P, Constine LS, Fajardo LF, Phi llips TL, Wasserman TH. RTOG Late Effects Working Group. Overview. Late Effects of \nNormal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys. 1995;31(5):1041 -2. Epub 1995/03/30.  \n316. The National Cancer Institute. Cancer Therapy Evaluation Program me. [cited 11 August 2006]. Available from url: \nhttp://ctep.info.nih.gov . \n317. Wiernik G, Bates TD, Bleehen NM, Brindle JM, Bullimore J, Fowler JF, et al. Final report of the general clinical results of t he \nBritish In stitute of Radiology fractionation study of 3F/wk versus 5F/wk in radiotherapy of carcinoma of the laryngo -pharynx. The \nBritish journal of radiology. 1990;63(747):169 -80. Epub 1990/03/01.  \n318. Rezvani M, Alcock CJ, Fowler JF, Haybittle JL, Hopewell JW, Wie rnik G. Normal tissue reactions in the British Institute of \nRadiology Study of 3 fractions per week versus 5 fractions per week in the treatment of carcinoma of the laryngo -pharynx by \nradiotherapy. The British journal of radiology. 1991;64(768):1122 -33. Ep ub 1991/12/01.  \n319. Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: the Christie \nand Royal Marsden Hospital Experience. Radiother Oncol. 2003;68(2):105 -11. Epub 2003/09/16.  \n320. Stuschke M, Thame s HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J \nRadiat Oncol Biol Phys. 1997;37(2):259 -67. Epub 1997/01/15.  \n321. Cancer Care Ontario Practice Guidelines Initiative. Accelerated radiotherapy for locall y advanced squamous cell carcinoma \nof the head and neck, revised 2002. 2002. [cited 11 August 2006]. Available from url: http://www.cancercare.on.ca/pdf/full5_6c.pdf . \n322. Overgaard J, Hansen HS, Sp echt L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of \nconventional radiotherapy of squamous -cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. \n2003;362(9388):933 -40. Epub 2003/09/27.  \n323. Hliniak A, Gwiazdowska B, Szutkowski Z, Kraszewska E, Kukolowicz P, Jarzabski A, et al. A multicentre \nrandomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 \nweek shortening ove rall time. Radiother Oncol. 2002;62(1):1 -10. Epub 2002/02/07.  \n324. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, et al. Accelerated fractionation (AF) \ncompared to conventional fractionation (CF) improves loco -regional c ontrol in the radiotherapy of advanced head and neck cancers: \nresults of the EORTC 22851 randomized trial. Radiother Oncol. 1997;44(2):111 -21. Epub 1997/08/01.  \n325. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or  accelerated radiotherapy in \nhead and neck cancer: a meta -analysis. Lancet. 2006;368(9538):843 -54. Epub 2006/09/05.  \n326. Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral \ncavity and oroph aryngeal cancer: radiotherapy. Cochrane Database Syst Rev. 2010(12):CD006387. Epub 2010/12/15.  \n327. Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, et al. A prospective study of salivary function sparing in \npatients with head -and-neck cancers r eceiving intensity -modulated or three -dimensional radiation therapy: initial results. Int J Radiat \nOncol Biol Phys. 2001;49(4):907 -16. Epub 2001/03/10.  \n328. Chen YJ, Kuo JV, Ramsinghani NS, Al -Ghazi MS. Intensity -modulated radiotherapy for previously irrad iated, recurrent head -\nand-neck cancer. Medical dosimetry : official journal of the American Association of Medical Dosimetrists. 2002;27(2):171 -6. Epub \n2002/06/21.  \n329. Podd TJ, Carton AT, Barrie R, Dawes PK, Roberts JT, Stassen LF, et al. Treatment of ora l cancers using iridium -192 \ninterstitial irradiation. Br J Oral Maxillofac Surg. 1994;32(7947563):207 -13. Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  34 \n330. Shibuya H, Hoshina M, Takeda M, Matsumoto S, Suzuki S, Okada N. Brachytherapy for stage I & II oral tongue cancer: an \nanalysis of past cases focu sing on control and complications. Int J Radiat Oncol Biol Phys. 1993;26(1):51 -8. \n331. Pernot M, Hoffstetter S, Peiffert D, Luporsi E, Marchal C, Kozminski P, et al. Epidermoid carcinomas of the floor of mouth \ntreated by exclusive irradiation: statistical study of a series of 207 cases. Radiother Oncol. 1995;35(7480819):177 -85. \n332. Mazeron JJ, Crook JM, Benck V, Marinello G, Martin M, Raynal M, et al. Iridium 192 implantation of T1 and T2 carcinomas \nof the mobile tongue. Int J Radiat Oncol Biol Phys. 1990; 19(6):1369 -76. \n333. Matsumoto S, Takeda M, Shibuya H, Suzuki S. T1 and T2 squamous cell carcinomas of the floor of the mouth: results of \nbrachytherapy mainly using 198Au grains. Int J Radiat Oncol Biol Phys. 1996;34(8598360):833 -41. \n334. Leung TW, Wong VY,  Kwan KH, Ng TY, Wong CM, Tung SY, et al. High dose rate brachytherapy for early stage oral tongue \ncancer. Head Neck. 2002;24(3):274 -81. Epub 2002/03/14.  \n335. Hareyama M, Nishio M, Saito A, Kagami Y, Asano K, Oouchi A, et al. Results of cesium needle inter stitial implantation for \ncarcinoma of the oral tongue. Int J Radiat Oncol Biol Phys. 1993;25(1):29 -34. \n336. Bachaud JM, Delannes M, Allouache N, Benchalal M, Alzieu C, David JM, et al. Radiotherapy of stage I and II carcinomas of \nthe mobile tongue and/or f loor of the mouth. Radiother Oncol. 1994;31(3):199 -206. \n337. Pernot M, Malissard L, Hoffstetter S, Luporsi E, Peiffert D, Aletti P, et al. The study of tumoral, radiobiological, and gene ral \nhealth factors that influence results and complications in a serie s of 448 oral tongue carcinomas treated exclusively by irradiation. \nInt J Radiat Oncol Biol Phys. 1994;29(4):673 -9. Epub 1994/07/01.  \n338. Pernot M, Luporsi E, Hoffstetter S, Peiffert D, Aletti P, Marchal C, et al. Complications following definitive irradia tion for \ncancers of the oral cavity and the oropharynx (in a series of 1134 patients). Int J Radiat Oncol Biol Phys. 1997;37(3):577 -85. Epub \n1997/02/01.  \n339. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, et al. An analysis of mandibular  bone complications in \nradiotherapy for T1 and T2 carcinoma of the oral tongue. Int J Radiat Oncol Biol Phys. 1996;34(2):333 -9. Epub 1996/01/15.  \n340. Mazeron JJ, Crook J, Martin M, Peynegre R, Pierquin B. Iridium 192 implantation of squamous cell carcinoma s of the \noropharynx. Am J Otolaryngol. 1989;10(5):317 -21. Epub 1989/09/01.  \n341. Pernot M, Malissard L, Taghian A, Hoffstetter S, Luporsi E, Forcard JJ, et al. Velotonsillar squamous cell carcinoma: 277 \ncases treated by combined external irradiation and brachytherapy --results according to extension, localization, and dose rate. Int J \nRadiat Oncol Biol Phys. 1992;23(4):715 -23. Epub 1992/01/01.  \n342. Hammerlid E, Mercke C, Sullivan M, Westin T. A prospective quality of life study of patients with oral or pharyngeal \ncarcinoma treated with external beam irradiation with or without brachytherapy. Oral Oncol. 1997;33(3):189 -96. Epub 1997/05/01.  \n343. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squam ous-\ncell carcinoma: three meta -analyses of updated individual data. MACH -NC Collaborative Group. Meta -Analysis of Chemotherapy on \nHead and Neck Cancer. Lancet. 2000;355(9208):949 -55. Epub 2000/04/18.  \n344. Bourhis J, Amand C, Pignon JP. Update of MACH -NC (M eta-Analysis of Chemotherapy in Head and Neck Cancer) database \nfocused on concomitant chemoradiotherapy: 5505. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post -Meeting Edition) \n2004;22(14S (July 15 Supplement)).  \n345. Pignon JP, le Maitre A, Maillard  E, Bourhis J. Meta -analysis of chemotherapy in head and neck cancer (MACH -NC): an update \non 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4 -14. Epub 2009/05/19.  \n346. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhi s J, et al. Meta -analysis of chemotherapy in head and \nneck cancer (MACH -NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33 -40. Epub 2011/06/21.  \n347. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta -analysis of hyperfractionat ed and accelerated radiotherapy and \ncombined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. \nBMC cancer. 2006;6:28. Epub 2006/02/02.  \n348. Cancer Care Ontario Practice Guidelines Initiative . Concomitant chemotherapy and radiotherapy in squamous cell head and \nneck cancer (excluding nasopharynx). 2000. [cited 11 August 2006]. Available from url: \nhttp://www.cancercare.on.ca/pdf/sumry5_ 6c.pdf . \n349. Henk JM, Bishop K, Shepherd SF. Treatment of head and neck cancer with CHART and nimorazole: phase II study. \nRadiother Oncol. 2003;66(1):65 -70. Epub 2003/02/01.  \n350. Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, et al. Locoregional ly advanced carcinoma of the oropharynx: \nconventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy --a \nmulticenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(1):78 -92. Epub 2002/12/31 . \n351. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus \nradiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16(4):1318 -24. Epub \n1998/04/29.  \n352. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or \nwithout concurrent low -dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective \nrandomized trial. J Clin Oncol. 2000;18(7):1458 -64. Epub 2000/03/29.  \n353. Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, et al. Radiotherapy with or without mitomycin \nc in the treatment of locally advanced head and neck cancer: resul ts of the IAEA multicentre randomised trial. Radiother Oncol. \n2003;67(1):17 -26. Epub 2003/05/22.  \n354. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus \nconcomitant chemotherapy and radiation t herapy for advanced -stage oropharynx carcinoma. Journal of the National Cancer Institute. \n1999;91(24):2081 -6. Epub 1999/12/22.  \n355. Zakotnik B, Smid L, Budihna M, Lesnicar H, Soba E, Furlan L, et al. Concomitant radiotherapy with mitomycin C and \nbleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys. \n1998;41(5):1121 -7. Epub 1998/08/27.  \n356. Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera -Fountzila A, Samantas E, et al. Concomitant  radiochemotherapy \nvs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol . \n2004;21(2):95 -107. Epub 2004/08/10.  \n357. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the man agement of squamous cell carcinoma of the head \nand neck region. A meta -analysis of prospective and randomized trials. J Clin Oncol. 1996;14(3):838 -47. Epub 1996/03/01.  \n358. Yu E, Shenouda G, Beaudet MP, Black MJ. Impact of radiation therapy fraction size o n local control of early glottic \ncarcinoma. Int J Radiat Oncol Biol Phys. 1997;37(3):587 -91. Epub 1997/02/01.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  35 \n359. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr., Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard \nradiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck \ncancer. J Clin Oncol. 2003;21(1):92 -8. Epub 2002/12/31.  \n360. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemoth erapy and radiotherapy for \norgan preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091 -8. Epub 2003/12/03.  \n361. Gupta NK, Swindell R. Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15 -year follow -up \nof a ra ndomized clinical trial. Clin Oncol (R Coll Radiol). 2001;13(5):339 -44. Epub 2001/11/22.  \n362. Vermorken JB, Remenar E, Van Herpen C, J GL, Stewart S, Gorlia T, et al. Standard cisplatin/infusional 5 -fluorouracil (PF) vs \ndocetaxel (T) plus PF (TPF) as neoad juvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head \nand neck (LA -SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Abstract No: 5508. Journal of \nClinical Oncology, 2004 ASCO Annual Meet ing Proceedings (Post -Meeting Edition) 2004;22(14S July 15 Supplement).  \n363. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous -cell \ncarcinoma of the head and neck. N Engl J Med. 2006;354(6):567 -78. Epub 2006/02/10.  \n364. Bartelink H, Breur K, Hart G, Annyas B, van Slooten E, Snow G. The value of postoperative radiotherapy as an adjuvant to \nradical neck dissection. Cancer. 1983;52(6):1008 -13. \n365. Jesse RH, Fletcher GH. Treatment of the neck in patie nts with squamous cell carcinoma of the head and neck. Cancer. \n1977;39(Suppl 2):868 -72. \n366. Lundahl RE, Foote RL, Bonner JA, Suman VJ, Lewis JE, Kasperbauer JL, et al. Combined neck dissection and postoperative \nradiation therapy in the management of the h igh-risk neck: a matched -pair analysis. Int J Radiat Oncol Biol Phys. \n1998;40(9486600):529 -34. \n367. Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, et al. Evaluation of the dose for postoperative \nradiation therapy of head and neck cance r: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26(1):3 -\n11. Epub 1993/04/30.  \n368. Sanguineti G, Richetti A, Bignardi M, Corvo R, Gabriele P, Sormani MP, et al. Accelerated versus conventional fractionated \npostoperative  radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys. \n2005;61(3):762 -71. Epub 2005/02/15.  \n369. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressi ng risk features and time \nfactors of surgery plus radiotherapy in advanced head -and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):571 -8. Epub \n2001/10/13.  \n370. Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM, et al. Accelerated hyperfractionation (AHF) compared \nto conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of \nproliferation. Br J Cancer. 2002;86(4):517 -23. Epub 2002/03/01.  \n371. Bataini JP, Bernier J, Assela in B, Lave C, Jaulerry C, Brunin F, et al. Primary radiotherapy of squamous cell carcinoma of the \noropharynx and pharyngolarynx: tentative multivariate modelling system to predict the radiocurability of neck nodes. Int J Ra diat \nOncol Biol Phys. 1988;14(335 0718):635 -42. \n372. Bachaud JM, Cohen -Jonathan E, Alzieu C, David JM, Serrano E, Daly -Schveitzer N. Combined postoperative radiotherapy and \nweekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Rad iat Oncol Biol \nPhys. 1996;36(5):999 -1004. Epub 1996/12/01.  \n373. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head  \nand neck cancers: a comparative analysis of concurrent postoperati ve radiation plus chemotherapy trials of the EORTC (#22931) and \nRTOG (# 9501). Head Neck. 2005;27(10):843 -50. Epub 2005/09/15.  \n374. Chow JM, Levin BC, Krivit JS, Applebaum EL. Radiotherapy or surgery for subclinical cervical node metastases. Arch \nOtolaryngol Head Neck Surg. 1989;115(8):981 -4. Epub 1989/08/01.  \n375. Bernier J. [Adjuvant treatment of head and neck cancers: advances and challenges]. Bull Cancer. 2007;94(9):823 -7. Epub \n2007/09/20. Le traitement adjuvant des carcinomes ORL localement ava nces: acquis et challenges.  \n376. Huang DT, Johnson CR, Schmidt -Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with \nextracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Bio l Phys. \n1992;23(4):737 -42. \n377. Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al. Randomized study of preoperative versus \npostoperative radiation therapy in advanced head and neck carcinoma: long -term follow -up of RTOG study 73 -03. Int J Radiat Oncol \nBiol Phys. 1991;20(1):21 -8. Epub 1991/01/01.  \n378. Peters LJ, Weber RS, Morrison WH, Byers RM, Garden AS, Goepfert H. Neck surgery in patients with primary oropharyngeal \ncancer treated by radiotherapy. Head Neck. 1996;18(6):552 -9. Epub 19 96/11/01.  \n379. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. Clin Otolaryngol \nAllied Sci. 1982;7(3):185 -92. Epub 1982/06/01.  \n380. Goffinet DR, Fee WE, Jr., Goode RL. Combined surgery and postoperative  irradiation in the treatment of cervical lymph \nnodes. Arch Otolaryngol. 1984;110(11):736 -8. Epub 1984/11/01.  \n381. Barzan L, Talamini R. Analysis of prognostic factors for recurrence after neck dissection. Arch Otolaryngol Head Neck Surg. \n1996;122(12):1299 -302. Epub 1996/12/01.  \n382. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Postoperative irradiation for squamous cell \ncarcinoma of the oral cavity: 35 -year experience. Head Neck. 2004;26(11):984 -94. Epub 2004/10/02.  \n383. Close L G, Brown PM, Vuitch MF, Reisch J, Schaefer SD. Microvascular invasion and survival in cancer of the oral cavity and \noropharynx. Arch Otolaryngol Head Neck Surg. 1989;115(11):1304 -9. Epub 1989/11/01.  \n384. Foote RL, Buskirk SJ, Stanley RJ, Grambsch PM, Olsen  KD, DeSanto LW, et al. Patterns of failure after total laryngectomy for \nglottic carcinoma. Cancer. 1989;64(1):143 -9. Epub 1989/07/01.  \n385. Fietkau R, Lautenschl\u00e4ger C, Sauer R, Dunst J, Becker A, MBaumann M, et al. Postoperative concurrent radiochemothera py \nversus radiotherapy in high -risk SCCA of the head and neck: Results of the German phase III trial ARO 96 -3. J Clin Oncol, 2006 ASCO \nAnnual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement), 2006: 5507.  \n386. Mazeron JJ, Crook JM, Marinello G , Walop W, Pierquin B. Prognostic factors of local outcome for T1, T2 carcinomas of oral \ntongue treated by iridium 192 implantation. Int J Radiat Oncol Biol Phys. 1990;19(2):281 -5. Epub 1990/08/01.  \n387. Fisher J, Scott C, Scarantino CW, Leveque FG, White R L, Rotman M, et al. Phase III quality -of-life study results: impact on \npatients' quality of life to reducing xerostomia after radiotherapy for head -and-neck cancer --RTOG 97 -09. Int J Radiat Oncol Biol Phys. \n2003;56(3):832 -6. Epub 2003/06/06.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  36 \n388. Cancer Ca re Ontario Practice Guidelines Initiative. Symptomatic treatment of radiation -induced xerostomia in head and \nneck cancer patients (revised). 2002. [cited 11 August 2006]. Available from url: http:/ /www.cancercare.on.ca/pdf/pebc5 -8s.pdf . \n389. Tong AC, Leung AC, Cheng JC, Sham J. Incidence of complicated healing and osteoradionecrosis following tooth extraction \nin patients receiving radiotherapy for treatment of nasopharyngeal carcinoma. Australian de ntal journal. 1999;44(3):187 -94. Epub \n1999/12/11.  \n390. Epstein JB, Silverman S, Jr., Paggiarino DA, Crockett S, Schubert MM, Senzer NN, et al. Benzydamine HCl for prophylaxis of \nradiation -induced oral mucositis: results from a multicenter, randomized, doub le-blind, placebo -controlled clinical trial. Cancer. \n2001;92(4):875 -85. Epub 2001/09/11.  \n391. Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra -arterial \nchemotherapy. International journal of ti ssue reactions. 1987;9(2):115 -9. Epub 1987/01/01.  \n392. Kim JH, Chu FC, Lakshmi V, Houde R. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the \noropharynx. Am J Clin Oncol. 1986;9(2):132 -4. Epub 1986/04/01.  \n393. Sutherland SE, Browm an GP. Prophylaxis of oral mucositis in irradiated head -and-neck cancer patients: a proposed \nclassification scheme of interventions and meta -analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys. \n2001;49(4):917 -30. Epub 2001/03/10.  \n394. Cancer Care Ontario Practice Guidelines Initiative. The role of amifostine as a radioprotectant in the management of \npatients with squamous cell head and neck cancer. Practice Guideline Report #5 -8 - 2004 Update. 2004. [cited 11 August 2006]. \nAvailable from url: http://www.cancercare.on.ca/pdf/pebc5 -8f.pdf . \n395. Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving \ntreatment (Cochrane Revi ew). In: The Cochrane Library, Issue 2, 2005. Chichester: John Wiley & Sons Ltd.  \n396. Sprinzl GM, Galvan O, de Vries A, Ulmer H, Gunkel AR, Lukas P, et al. Local application of granulocyte -macrophage colony \nstimulating factor (GM -CSF) for the treatment of oral mucositis. Eur J Cancer. 2001;37(16):2003 -9. Epub 2001/10/13.  \n397. Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage -colony stimulating factor (GM -\nCSF) and sucralfate in prevention of radiation -induced mucositis: a  prospective randomized study. Int J Radiat Oncol Biol Phys. \n2000;46(3):525 -34. Epub 2000/03/04.  \n398. Grotz KA, Wustenberg P, Kohnen R, Al -Nawas B, Henneicke -von Zepelin HH, Bockisch A, et al. Prophylaxis of radiogenic \nsialadenitis and mucositis by coumari n/troxerutine in patients with head and neck cancer --a prospective,randomized, placebo -\ncontrolled, double -blind study. Br J Oral Maxillofac Surg. 2001;39(1):34 -9. Epub 2001/02/17.  \n399. Kaushal V, Verma K, Manocha S, Hooda HS, Das BP. Clinical evaluation of  human placental extract (placentrex) in radiation -\ninduced oral mucositis. International journal of tissue reactions. 2001;23(3):105 -10. Epub 2001/08/24.  \n400. Kostrica R, Rottenberg J, Kvech J, Betka J, Jablonicky P. Randomised, double -blind comparison of efficacy and tolerability of \ndiclofenac mouthwash versus placebo in mucositis of oral cavity by radiotherapy. J Clin Res 2002;5(1 -15):1 -15. \n401. Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte -macrophage colony -stimulating  factor \nand sucralfate mouthwashes in the prevention of radiation -induced mucositis: a double -blind prospective randomized phase III \nstudy. Int J Radiat Oncol Biol Phys. 2002;54(2):479 -85. Epub 2002/09/24.  \n402. Stokman MA, Spijkervet FK, Burlage FR, Dijkst ra PU, Manson WL, de Vries EG, et al. Oral mucositis and selective elimination \nof oral flora in head and neck cancer patients receiving radiotherapy: a double -blind randomised clinical trial. Br J Cancer. \n2003;88(7):1012 -6. Epub 2003/04/03.  \n403. Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shiba G, et al. Radiation -induced mucositis: a randomized \nclinical trial of micronized sucralfate versus salt & soda mouthwashes. Cancer investigation. 2003;21(1):21 -33. Epub 2003/03/20.  \n404. El-Sayed S, Nabi d A, Shelley W, Hay J, Balogh J, Gelinas M, et al. Prophylaxis of radiation -associated mucositis in \nconventionally treated patients with head and neck cancer: a double -blind, phase III, randomized, controlled trial evaluating the \nclinical efficacy of an an timicrobial lozenge using a validated mucositis scoring system. J Clin Oncol. 2002;20(19):3956 -63. Epub \n2002/09/28.  \n405. Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation -induced oropharyngeal mucositis: a \nprospective, p lacebo -controlled, randomized study. Int J Radiat Oncol Biol Phys. 2004;58(1):167 -74. Epub 2003/12/31.  \n406. Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan \nHCl oral solution for red ucing the severity of oral mucositis in patients receiving radiotherapy for head -and-neck malignancy. Int J \nRadiat Oncol Biol Phys. 2004;58(3):674 -81. Epub 2004/02/18.  \n407. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral candidiasis  for patients with cancer receiving \ntreatment. Cochrane Database Syst Rev. 2002(3):CD003807. Epub 2002/07/26.  \n408. Roy I, Fortin A, Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized \nstudy. Radiother Oncol.  2001;58(3):333 -9. Epub 2001/03/07.  \n409. Graham P, Browne L, Capp A, Fox C, Graham J, Hollis J, et al. Randomized, paired comparison of No -Sting Barrier Film \nversus sorbolene cream (10% glycerine) skin care during postmastectomy irradiation. Int J Radiat O ncol Biol Phys. 2004;58(1):241 -6. \nEpub 2003/12/31.  \n410. Williams MS, Burk M, Loprinzi CL, Hill M, Schomberg PJ, Nearhood K, et al. Phase III double -blind evaluation of an aloe vera \ngel as a prophylactic agent for radiation -induced skin toxicity. Int J Radi at Oncol Biol Phys. 1996;36(2):345 -9. Epub 1996/09/01.  \n411. Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity \nof erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol. 2004;73(2):153 -62. Epub 2004/11/16.  \n412. Goodwin WJ, Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: \nwhen do the ends justify the means? Laryngoscope. 2000;110(3 Pt 2 Suppl 93):1 -18. Epub 2000/03/14.  \n413. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, et al. Postoperative complications after en bloc salvage \nsurgery for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2003;129(12):1317 -21. Epub 2003/12/17.  \n414. Peiffert D, Pernot M, Malissard L, Aletti P, Hoffstetter S, Kozminski P, et al. Salvage irradiation by brachytherapy of \nvelotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases. Int J Radiat Oncol Biol Phys. \n1994;29(4):6 81-6. Epub 1994/07/01.  \n415. Mazeron JJ, Langlois D, Glaubiger D, Huart J, Martin M, Raynal M, et al. Salvage irradiation of oropharyngeal cancers using \niridium 192 wire implants: 5 -year results of 70 cases. Int J Radiat Oncol Biol Phys. 1987;13(7):957 -62. Epub 1987/07/01.  \n416. Haraf DJ, Weichselbaum RR, Vokes EE. Re -irradiation with concomitant chemotherapy of unresectable recurrent head and \nneck cancer: a potentially curable disease. Annals of oncology : official journal of the European Society for Medical  Oncology / ESMO. \n1996;7(9):913 -8. Epub 1996/11/01.  \n417. Pomp J, Levendag PC, van Putten WL. Reirradiation of recurrent tumors in the head and neck. Am J Clin Oncol. \n1988;11(5):543 -9. Epub 1988/10/01.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  37 \n418. Stevens KR, Jr., Britsch A, Moss WT. High -dose rei rradiation of head and neck cancer with curative intent. Int J Radiat Oncol \nBiol Phys. 1994;29(4):687 -98. Epub 1994/07/01.  \n419. Emami B, Bignardi M, Spector GJ, Devineni VR, Hederman MA. Reirradiation of recurrent head and neck cancers. \nLaryngoscope. 1987; 97(1):85 -8. Epub 1987/01/01.  \n420. Dawson LA, Myers LL, Bradford CR, Chepeha DB, Hogikyan ND, Teknos TN, et al. Conformal re -irradiation of recurrent and \nnew primary head -and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(2):377 -85. Epub 2001/05/31.  \n421. Ohizumi Y, Tamai Y, Imamiya S, Akiba T. Complications following re -irradiation for head and neck cancer. Am J \nOtolaryngol. 2002;23(4):215 -21. Epub 2002/07/10.  \n422. Mohanti BK, Umapathy H, Bahadur S, Thakar A, Pathy S. Short course palliative radiotherapy  of 20 Gy in 5 fractions for \nadvanced and incurable head and neck cancer: AIIMS study. Radiother Oncol. 2004;71(3):275 -80. Epub 2004/06/03.  \n423. Laccourreye O, Lawson G, Muscatello L, Biacabe B, Laccourreye L, Brasnu D. Carbon dioxide laser debulking for \nobstructing endolaryngeal carcinoma: a 10 -year experience. Ann Otol Rhinol Laryngol. 1999;108(5):490 -4. Epub 1999/05/21.  \n424. Wilner HI, Lazo A, Metes JJ, Beil KA, Nowack P, Jacobs J. Embolization in cataclysmal hemorrhage caused by squamous cell \ncarcinomas  of the head and neck. Radiology. 1987;163(3):759 -62. Epub 1987/06/01.  \n425. Citardi MJ, Chaloupka JC, Son YH, Ariyan S, Sasaki CT. Management of carotid artery rupture by monitored endovascular \ntherapeutic occlusion (1988 -1994). Laryngoscope. 1995;105(10): 1086 -92. Epub 1995/10/01.  \n426. Morrissey DD, Andersen PE, Nesbit GM, Barnwell SL, Everts EC, Cohen JI. Endovascular management of hemorrhage in \npatients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1997;123(1):15 -9. Epub 1997/01/01.  \n427. Paiva MB, Blackwell KE, Saxton RE, Calcaterra TC, Ward PH, Soudant J, et al. Palliative laser therapy for recurrent head and \nneck cancer: a Phase II clinical study. Laryngoscope. 1998;108(9):1277 -83. Epub 1998/09/17.  \n428. Paleri V, Stafford FW, Sammut MS. Laser debulking in malignant upper airway obstruction. Head Neck. 2005;27(4):296 -\n301. Epub 2005/01/27.  \n429. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5 -FU in end \nstage squamous carcinoma of the  head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer. 1990;61(2):311 -5. Epub \n1990/02/01.  \n430. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, \nmethotrexate, bleomycin a nd vincristine (CABO) versus cisplatin and 5 -fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic \nsquamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Annals o f \noncology : officia l journal of the European Society for Medical Oncology / ESMO. 1994;5(6):521 -6. Epub 1994/07/01.  \n431. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus \nfluorouracil and carboplatin plus f luorouracil versus methotrexate in advanced squamous -cell carcinoma of the head and neck: a \nSouthwest Oncology Group study. J Clin Oncol. 1992;10(8):1245 -51. Epub 1992/08/01.  \n432. Jacobs C, Lyman G, Velez -Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing \ncisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J C lin \nOncol. 1992;10(2):257 -63. Epub 1992/02/01.  \n433. Schornagel JH, Verweij J, de Mulder PH, Cognetti F, Vermorken JB, Cappelaere P, et al. Randomized phase III trial of \nedatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a \nEuropean Organization for Research and Treatment of Can cer Head and Neck Cancer Cooperative Group study. J Clin Oncol. \n1995;13(7):1649 -55. Epub 1995/07/01.  \n434. Jelic S, Stamatovic L, Vucicevic S, Petrovic Z, Kreacic M, Babovic N, et al. Use of high -dose cytarabine to enhance cisplatin \ncytotoxicity -effects on the response and overall survival rates of advanced head and neck cancer patients. Eur J Cancer. \n2002;38(11):1478 -89. Epub 2002/07/12.  \n435. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plu s \nfluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Co operative \nOncology Group. J Clin Oncol. 2005;23(15):3562 -7. Epub 2005/05/24.  \n436. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high -dose paclitaxel \n+ cisplatin + granulocyte colony -stimulating factor versus low -dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern \nCooperative Oncology Group Study E1393. J Clin On col. 2001;19(4):1088 -95. Epub 2001/02/22.  \n437. Boysen M, Lovdal O, Tausjo J, Winther F. The value of follow -up in patients treated for squamous cell carcinoma of the \nhead and neck. Eur J Cancer. 1992;28(2 -3):426 -30. Epub 1992/01/01.  \n438. Hammerlid E, Perss on LO, Sullivan M, Westin T. Quality -of-life effects of psychosocial intervention in patients with head \nand neck cancer. Otolaryngol Head Neck Surg. 1999;120(4):507 -16. Epub 1999/04/03.  \n439. Hammerlid E, Silander E, Hornestam L, Sullivan M. Health -related quality of life three years after diagnosis of head and \nneck cancer --a longitudinal study. Head Neck. 2001;23(2):113 -25. Epub 2001/04/17.  \n440. Bjordal K, Ahlner -Elmqvist M, Hammerlid E, Boysen M, Evensen JF, Biorklund A, et al. A prospective study of quali ty of life \nin head and neck cancer patients. Part II: Longitudinal data. Laryngoscope. 2001;111(8):1440 -52. Epub 2001/09/25.  \n441. Smit M, Balm AJ, Hilgers FJ, Tan IB. Pain as sign of recurrent disease in head and neck squamous cell carcinoma. Head \nNeck. 20 01;23(5):372 -5. Epub 2001/04/11.  \n442. Nguyen NP, Sallah S, Karlsson U, Antoine JE. Combined chemotherapy and radiation therapy for head and neck \nmalignancies: quality of life issues. Cancer. 2002;94(4):1131 -41. Epub 2002/03/29.  \n443. Stokkel MP, Terhaard CH , Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine -18 \nfluorodeoxyglucose dual -head positron emission tomography. Eur J Nucl Med. 1999;26(7):767 -73. Epub 1999/07/10.  \n444. Shah SI, Applebaum EL. Lung cancer after h ead and neck cancer: role of chest radiography. Laryngoscope. \n2000;110(12):2033 -6. Epub 2000/12/29.  \n445. Merkx MA, Boustahji AH, Kaanders JH, Joosten F, Marres HA, Bruaset I, et al. A half -yearly chest radiograph for early \ndetection of lung cancer followin g oral cancer. Int J Oral Maxillofac Surg. 2002;31(4):378 -82. Epub 2002/10/04.  \n446. Gottschlich S, Maune S, Maass JD, Gorogh T, Hoffmann M, Hoffmann -Fazel A, et al. Serum p53 autoantibodies in the \nfollow -up of head and neck cancer patients. Oncology. 2000; 59(1):31 -5. Epub 2000/07/15.  \n447. Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC -Ag, CEA, CA 19.9 and CA 125 for \ndiagnosis and follow -up in oral cancer. J Craniomaxillofac Surg. 1998;26(4):243 -8. Epub 1998/10/20.  \n448. Mayne ST, Cartmel B, Baum M, Shor -Posner G, Fallon BG, Briskin K, et al. Randomized trial of supplemental beta -carotene \nto prevent second head and neck cancer. Cancer Res. 2001;61(4):1457 -63. Epub 2001/03/14.  \n449. Allison PJ, Locker D, Feine JS. The relationship  between dental status and health -related quality of life in upper \naerodigestive tract cancer patients. Oral Oncol. 1999;35(2):138 -43. Epub 1999/08/06.  Referenzen  \n\u00a9 Leitlinienprogramm Onkologie | S3 Leitlinie Mundh\u00f6h lenkarzinom | Kurzversion | September  2012  38 \n450. Granstrom G. Radiotherapy, osseointegration and hyperbaric oxygen therapy. Periodontology 2000. 200 3;33:145 -62. \nEpub 2003/09/03.  \n451. Mericske -Stern R, Perren R, Raveh J. Life table analysis and clinical evaluation of oral implants supporting prostheses after \nresection of malignant tumors. The International journal of oral & maxillofacial implants. 1999 ;14(5):673 -80. Epub 1999/10/26.  \n452. McCord JF, Michelinakis G. Systematic review of the evidence supporting intra -oral maxillofacial prosthodontic care. The \nEuropean journal of prosthodontics and restorative dentistry. 2004;12(3):129 -35. Epub 2004/11/04.  \n453. Rosenberg SW. Oral complications of cancer therapies. Chronic dental complications. NCI monographs : a publication of \nthe National Cancer Institute. 1990(9):173 -8. Epub 1990/01/01.  \n454. Toljanic JA, Heshmati RH, Bedard JF. Dental follow -up compliance in a population of irradiated head and neck cancer \npatients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(1):35 -8. Epub 2002/01/24.  \n455. Ang E, Black C, Irish J, Brown DH, Gullane P, O'Sullivan B, et al. Reconstructive options in the treatment  of \nosteoradionecrosis of the craniomaxillofacial skeleton. British journal of plastic surgery. 2003;56(2):92 -9. Epub 2003/06/07.  \n456. Annane D, Depondt J, Aubert P, Villart M, Gehanno P, Gajdos P, et al. Hyperbaric oxygen therapy for radionecrosis of the \njaw: a randomized, placebo -controlled, double -blind trial from the ORN96 study group. J Clin Oncol. 2004;22(24):4893 -900. Epub \n2004/11/03.  \n457. Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. \nCochrane Database Syst Rev. 2005(3):CD005005. Epub 2005/07/22.  \n458. Coulthard P, Esposito M, Worthington HV, Jokstad A. Therapeutic use of hyperbaric oxygen for irradiated dental implant \npatients: a systematic review. Journal of dental education. 2 003;67(1):64 -8. Epub 2003/01/24.  \n459. Jereczek -Fossa BA, Orecchia R. Radiotherapy -induced mandibular bone complications. Cancer treatment reviews. \n2002;28(1):65 -74. Epub 2002/05/25.  \n460. Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the j aws as a side effect of radiotherapy of head and \nneck tumour patients --a report of a thirty year retrospective review. Int J Oral Maxillofac Surg. 2003;32(3):289 -95. Epub 2003/05/28.  \n461. Pasquier D, Hoelscher T, Schmutz J, Dische S, Mathieu D, Baumann M, et al. Hyperbaric oxygen therapy in the treatment of \nradio -induced lesions in normal tissues: a literature review. Radiother Oncol. 2004;72(1):1 -13. Epub 2004/07/09.  \n462. Royal College of Speech and Language Therapists. Clinical Guidelines. London: RCSLT; 2004. [cited 11 August 2006]. \nAvailable from url: http://www.rcslt.org/resources/RCSLT_Clinical_Guidelines.pdf . \n463. Sullivan P, Guildford A. Swallowing intervention in oncology. San Diego: Singular Publishing Group INC; 1999.  \n464. Kreuzer SH, Schima W, Schober E, Pokieser P, Kofler G, Lechner G, et al. Complications after laryngeal surgery: \nvideofluoroscopic evaluation of 120 patients. Clinical radiology. 2000;55(10):775 -81. Epub 20 00/10/29.  \n465. Stenson KM, MacCracken E, List M, Haraf DJ, Brockstein B, Weichselbaum R, et al. Swallowing function in patients with \nhead and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000;126(3):371 -7. Epub 2000/03/18.  \n466. Aviv JE.  Prospective, randomized outcome study of endoscopy versus modified barium swallow in patients with dysphagia. \nLaryngoscope. 2000;110(4):563 -74. Epub 2000/04/14.  \n467. Furia CL, Kowalski LP, Latorre MR, Angelis EC, Martins NM, Barros AP, et al. Speech intel ligibility after glossectomy and \nspeech rehabilitation. Arch Otolaryngol Head Neck Surg. 2001;127(7):877 -83. Epub 2001/08/04.  \n468. Eisbruch A, Lyden T, Bradford CR, Dawson LA, Haxer MJ, Miller AE, et al. Objective assessment of swallowing dysfunction \nand a spiration after radiation concurrent with chemotherapy for head -and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(1):23 -8. \nEpub 2002/05/15.  \n469. Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ, Karlsson U, et al. Dysphagia following chemoradiation for l ocally advanced \nhead and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004;15(3):3 83-8. \nEpub 2004/03/05.  \n470. Gillespie MB, Brodsky MB, Day TA, Lee FS, Martin -Harris B. Swallowing -related quality o f life after head and neck cancer \ntreatment. Laryngoscope. 2004;114(8):1362 -7. Epub 2004/07/29.  \n471. Kulbersh BD, Rosenthal EL, McGrew BM, Duncan RD, McColloch NL, Carroll WR, et al. Pretreatment, preoperative \nswallowing exercises may improve dysphagia qua lity of life. Laryngoscope. 2006;116(6):883 -6. Epub 2006/06/01.  \n472. Clinical Standards: food, fluid and nutritional care in hospitals. Edinburgh: NHS Quality Improvement Scotland; 2003. \n[cited 1 March 2004]. Available from url: http://www.nhshealthquality.org . \n473. Schweinfurth JM, Boger GN, Feustel PJ. Preoperative risk assessment for gastrostomy tube placement in head and neck \ncancer patients. Head Neck. 2001;23(5):376 -82. Epub 2001/04/11.  \n474. Deurloo EE, Sc hultze Kool LJ, Kroger R, van Coevorden F, Balm AJ. Percutaneous radiological gastrostomy in patients with \nhead and neck cancer. Eur J Surg Oncol. 2001;27(1):94 -7. Epub 2001/03/10.  \n475. Beaver ME, Myers JN, Griffenberg L, Waugh K. Percutaneous fluoroscopic  gastrostomy tube placement in patients with \nhead and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124(10):1141 -4. Epub 1998/10/17.  \n476. Lee JH, Machtay M, Unger LD, Weinstein GS, Weber RS, Chalian AA, et al. Prophylactic gastrostomy tubes in patient s \nundergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124(8):871 -5. Epub \n1998/08/26.  \n477. Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P. Enteral nutrition during the treatment of he ad and \nneck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer. 2001;91(9):1785 -90. \nEpub 2001/05/04.  \n478. Chawla S, Mohanti BK, Rakshak M, Saxena S, Rath GK, Bahadur S. Temporal assessment of quality of life o f head and neck \ncancer patients receiving radical radiotherapy. Quality of life research : an international journal of quality of life aspect s of treatment, \ncare and rehabilitation. 1999;8(1 -2):73 -8. Epub 1999/08/24.  \n479. Gritz ER, Carmack CL, de Moor C, C oscarelli A, Schacherer CW, Meyers EG, et al. First year after head and neck cancer: \nquality of life. J Clin Oncol. 1999;17(1):352 -60. Epub 1999/08/24.  \n480. Zwahlen RA, Dannemann C, Gratz KW, Studer G, Zwahlen D, Moergeli H, et al. Quality of life and psyc hiatric morbidity in \npatients successfully treated for oral cavity squamous cell cancer and their wives. J Oral Maxillofac Surg. 2008;66(6):1125 -32. Epub \n2008/05/20.  \n481. Singer S, Brown A, Einenkel J, Hauss J, Hinz A, Klein A, et al. Identifying tumor pat ients' depression. Supportive care in \ncancer : official journal of the Multinational Association of Supportive Care in Cancer. 2011;19(11):1697 -703. Epub 2010/09/21.  \n482. Spelten ER, Sprangers MA, Verbeek JH. Factors reported to influence the return to wor k of cancer survivors: a literature \nreview. Psycho -oncology. 2002;11(2):124 -31. Epub 2002/03/29.  \n483. Relic A, Mazemda P, Arens C, Koller M, Glanz H. Investigating quality of life and coping resources after laryngectomy. Eur \nArch Otorhinolaryngol. 2001;258 (10):514 -7. Epub 2002/02/07.  ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}